

Emër Mbiemër: **Adnan Kastrati**
Datëlindje: **25.11.1955**
Vendlindje: **Tiranë**
Viti i zgjedhjes: **2009**
Seksioni: **Shkencat natyrore dhe teknike**
Gjuhët : **Shqip, gjermanisht, anglisht, frëngjisht, italisht**
Kontakt: **Prof. dr. Adnan Kastrati**
Deutsches Herzzentrum, Technische Universität München



Adresa: Lazarettstr. 36, 80636 Mynih, Gjermani
Telefon: +49-89-12184577
Email: adnan.kastrati@akad.gov.al
Kastrati@dhm.mhn.de
Faqe zyrtare: www.akad.gov.al
<http://www.dhm.mhn.de/ww/en/pub/dhm.htm>

Diplomimi si “Mjek i përgjithshëm” në Fakultetin e Mjekësisë, Universiteti i Tiranës, 1979

Karriera profesionale:

Specializim në Mjekësi të Përgjithshme dhe Kardiologji, Poliklinika Qendrore dhe Qendra Spitalore Universitare në Tiranë, 1979-1983
Kardiolog, Qendra Spitalore Universitare në Tiranë, 1983-1991
Specializim në Kardiologji intervencionuese në Universitetin e Heidelbergut dhe Universitetin Teknik të Mynihut Gjermani, 1991-1993
Shef i Klinikës së Dytë të Kardiologjisë Qendra Spitalore Universitare në Tiranë, 1993
“Profesor i asociuar” në Kardiologji, Universiteti i Tiranës, 1994
“Profesor” në Kardiologji, Universiteti Teknik i Mynihut, 2000

Pozicioni aktual

Profesor në Kardiologji, Universiteti Teknik i Mynihut
Zv/shef i Departamentit të Kardiologjisë,
Shef, Laboratori i Katheterizimit
Drejtor i ISAResearch Center
Deutsches Herzzentrum, Universiteti Teknik i Mynihut

Anëtar i Bordeve botuese të:

Journal of the American College of Cardiology, European Heart Journal, Nature Reviews Cardiology, American Heart Journal, Circulation Cardiovascular Interventions , JACC Cardiovascular Interventions, Catheterization and Cardiovascular Interventions, Eurointervention, Acute Cardiac Care, Minerva Cardioangiologica

Çmime të marra

Sven-Effert Award in the field of Interventional Cardiology from German Society of Cardiology 2009
ETHICA Award – Interventional Cardiology from EuroPCR Paris 2014

Andreas Grüntzig Lecture in Interventional Cardiology from European Society of Cardiology Barcelona 2014

Paul-Morawitz Award in Cardiology from German Society of Cardiology 2015

Botime në peer-review journals

2015

1. Fiedler KA; Maeng M; Mehilli J; Schulz-Schupke S; Byrne RA; Sibbing D; Hoppmann P; Schneider S; Fusaro M; Ott I; Kristensen SD; Ibrahim T; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sarafoff N. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. *J Am Coll Cardiol* 2015;65:1619-29
2. Cassese S; Byrne RA; Ndrepepa G; Schunkert H; Fusaro M; Kastrati A. Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. *Clin Res Cardiol* 2015;
3. Aradi D; Kirtane A; Bonello L; Gurbel PA; Tantry US; Huber K; Freynhofer MK; Ten Berg J; Janssen P; Angiolillo DJ; Siller-Matula JM; Marcucci R; Patti G; Mangiacapra F; Valgimigli M; Morel O; Palmerini T; Price MJ; Cuisset T; Kastrati A; Stone GW; Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J* 2015;
4. Polsterl S; Singh M; Katouzian A; Navab N; Kastrati A; Ladic L; Kamen A. Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects. *BMC Med Inform Decis Mak* 2015;15:9
5. Ndrepepa G; Kastrati A. Activated clotting time during percutaneous coronary intervention: a test for all seasons or a mind tranquilizer? *Circ Cardiovasc Interv* 2015;8:
6. Watanabe H; Morimoto T; Natsuaki M; Furukawa Y; Nakagawa Y; Kadota K; Yamaji K; Ando K; Shizuta S; Shiomi H; Tada T; Tazaki J; Kato Y; Hayano M; Abe M; Tamura T; Shirotani M; Miki S; Matsuda M; Takahashi M; Ishii K; Tanaka M; Aoyama T; Doi O; Hattori R; Kato M; Suwa S; Takizawa A; Takatsu Y; Shinoda E; Eizawa H; Takeda T; Lee JD; Inoko M; Ogawa H; Hamasaki S; Horie M; Nohara R; Kambara H; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kastrati A; Kimura T; investigators CR-KPCrc-. Antiplatelet Therapy Discontinuation and the Risk of Serious Cardiovascular Events after Coronary Stenting: Observations from the CREDO-Kyoto Registry Cohort-2. *PLoS One* 2015;10:e0124314
7. Jochheim D; Abdel-Wahab M; Mehilli J; Ellert J; Wubken-Kleinfeld N; El-Mawardy M; Pache J; Massberg S; Kastrati A; Richardt G. Significant aortic regurgitation after transferal aortic valve implantation: patients' gender as independent risk factor. *Minerva Cardioangiol* 2015;
8. Ndrepepa G; Kastrati A. Minimising bleeding during percutaneous coronary intervention. *BMJ* 2015;350:h1395
9. Byrne RA; Kastrati A. Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. *Eur Heart J* 2015;
10. Kronzon I; Jelnin V; Ruiz CE; Saric M; Williams MR; Kasel AM; Shivaraju A; Colombo A; Kastrati A. Optimal imaging for guiding TAVR: transesophageal or transthoracic echocardiography, or just fluoroscopy? *JACC Cardiovasc Imaging* 2015;8:361-70
11. Kufner S; Cassese S; Groha P; Byrne RA; Schunkert H; Kastrati A; Ott I; Fusaro M. Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. *Cardiovasc Revasc Med* 2015;

12. Bradaric C; Kuhs K; Groha P; Dommasch M; Langwieser N; Haller B; Ott I; Fusaro M; Theiss W; von Beckerath N; Kastrati A; Laugwitz KL; Ibrahim T. Endovascular therapy for steno-occlusive subclavian and innominate artery disease. *Circ J* 2015;79:537-43
13. Stamatelopoulos K; Sibbing D; Rallidis LS; Georgiopoulos G; Stakos D; Braun S; Gatsiou A; Sopova K; Kotakos C; Varounis C; Tellis CC; Kastritis E; Alevizaki M; Tselepis AD; Alexopoulos P; Laske C; Keller T; Kastrati A; Dimmeler S; Zeiher AM; Stellos K. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. *J Am Coll Cardiol* 2015;65:904-16
14. Cassese S; Ndrepepa G; King LA; Nerad M; Schunkert H; Kastrati A; Ott I; Fusaro M. Proximal occlusion versus distal filter for cerebral protection during carotid stenting: updated meta-analysis of randomised and observational MRI studies. *EuroIntervention* 2015;10:
15. Schulz-Schupke S; Kastrati A; Instrumental Sealing of Arterial Puncture Site CDvMCTI. Assessing the benefit of vascular closure devices after femoral artery puncture--reply. *JAMA* 2015;313:855-6
16. Guha Roy A; Conjeti S; Carlier S; Dutta P; Kastrati A; Laine A; Navab N; Katouzian A; Sheet D. Lumen Segmentation in Intravascular Optical Coherence Tomography using Backscattering Tracked and Initialized Random Walks. *IEEE J Biomed Health Inform* 2015;
17. Ndrepepa G; Stephan T; Fiedler KA; Guerra E; Kufner S; Kastrati A. Procedure-related bleeding in elective percutaneous coronary interventions. *Eur J Clin Invest* 2015;45:263-73
18. StephanWindecker; Kolh P; Alfonso F; Collet JP; Cremer J; Falk V; Filippatos G; Hamm C; Head SJ; Juni P; Kappetein AP; Kastrati A; Knuuti J; Landmesser U; Laufer G; Neumann FJ; Richter DJ; Schauerte P; Uva MS; Stefanini GG; Taggart DP; Torracca L; Valgimigli M; Wijns W; Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. *Rev Esp Cardiol (Engl Ed)* 2015;68:144
19. Byrne RA; Kastrati A. Bioresorbable drug-eluting stents: an immature technology in need of mature application. *JACC Cardiovasc Interv* 2015;8:198-200
20. Kasel AM; Shivaraju A; von Scheidt W; Kastrati A; Thilo C. Anatomic guided crossing of a stenotic aortic valve under fluoroscopy: "right cusp rule, part III". *JACC Cardiovasc Interv* 2015;8:119-20
21. Schulz-Schupke S; Byrne RA; Ten Berg JM; Neumann FJ; Han Y; Adriaenssens T; Tolg R; Seyfarth M; Maeng M; Zrenner B; Jacobshagen C; Mudra H; von Hodenberg E; Wohrle J; Angiolillo DJ; von Merzljak B; Rifatov N; Kufner S; Morath T; Feuchtenberger A; Ibrahim T; Janssen PW; Valina C; Li Y; Desmet W; Abdel-Wahab M; Tiroch K; Hengstenberg C; Bernlochner I; Fischer M; Schunkert H; Laugwitz KL; Schomig A; Mehilli J; Kastrati A; on behalf of the Intracoronary S; Antithrombotic Regimen S; investigators EFoMDATAD-ESt. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. *Eur Heart J* 2015;
22. Ndrepepa G; Fusaro M; Cassese S; Guerra E; Schunkert H; Kastrati A. Relation of body mass index to bleeding during percutaneous coronary interventions. *Am J Cardiol* 2015;115:434-40
23. Ndrepepa G; Guerra E; Schulz S; Fusaro M; Cassese S; Kastrati A. Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. *J Thromb Thrombolysis* 2015;39:35-42

2014

1. Windecker S; Kolh P; Alfonso F; Collet JP; Cremer J; Falk V; Filippatos G; Hamm C; Head SJ; Juni P; Kappetein AP; Kastrati A; Knuuti J; Landmesser U; Laufer G; Neumann FJ; Richter DJ; Schauerte P;

- Uva MS; Stefanini GG; Taggart DP; Torracca L; Valgimigli M; Wijns W; Witkowski A. [2014 ESC/EACTS Guidelines on myocardial revascularization]. *Kardiol Pol* 2014;72:1253-379
2. Cassese S; De Luca G; Ribichini F; Cernigliaro C; Sansa M; Versaci F; Proietti I; Stankovic G; Stojkovic S; Fernandez-Pereira C; Tomai F; Vassanelli C; Antoniucci D; Serruys PW; Kastrati A; Rodriguez AE. ORAL immunosuppressive therapy to prevent in-Stent restenosis (RAMSES) cooperation: a patient-level meta-analysis of randomized trials. *Atherosclerosis* 2014;237:410-7
 3. Guerra E; Ndrepepa G; Schulz S; Byrne R; Hoppmann P; Kufner S; Ibrahim T; Tada T; Schunkert H; Laugwitz KL; Kastrati A. Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. *Am Heart J* 2014;168:862-8 e1
 4. Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. *EuroIntervention* 2014;
 5. Schulz-Schupke S; Helde S; Gewalt S; Ibrahim T; Linhardt M; Haas K; Hoppe K; Bottiger C; Groha P; Bradaric C; Schmidt R; Bott-Flugel L; Ott I; Goedel J; Byrne RA; Schneider S; Burgdorf C; Morath T; Kufner S; Joner M; Cassese S; Hoppmann P; Hengstenberg C; Pache J; Fusaro M; Massberg S; Mehilli J; Schunkert H; Laugwitz KL; Kastrati A; Instrumental Sealing of Arterial Puncture Site CDvMCTI. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. *JAMA* 2014;312:1981-7
 6. Myocardial Infarction Genetics Consortium I; Stitzel NO; Won HH; Morrison AC; Peloso GM; Do R; Lange LA; Fontanillas P; Gupta N; Duga S; Goel A; Farrall M; Saleheen D; Ferrario P; Konig I; Asselta R; Merlini PA; Marziliano N; Notarangelo MF; Schick U; Auer P; Assimes TL; Reilly M; Wilensky R; Rader DJ; Hovingh GK; Meitinger T; Kessler T; Kastrati A; Laugwitz KL; Siscovick D; Rotter JI; Hazen SL; Tracy R; Cresci S; Spertus J; Jackson R; Schwartz SM; Natarajan P; Crosby J; Muzny D; Ballantyne C; Rich SS; O'Donnell CJ; Abecasis G; Sunyaev S; Nickerson DA; Buring JE; Ridker PM; Chasman DI; Austin E; Ye Z; Kullo IJ; Weeke PE; Shaffer CM; Bastarache LA; Denny JC; Roden DM; Palmer C; Deloukas P; Lin DY; Tang ZZ; Erdmann J; Schunkert H; Danesh J; Marrugat J; Elosua R; Ardissino D; McPherson R; Watkins H; Reiner AP; Wilson JG; Altshuler D; Gibbs RA; Lander ES; Boerwinkle E; Gabriel S; Kathiresan S. Inactivating mutations in NPC1L1 and protection from coronary heart disease. *N Engl J Med* 2014;371:2072-82
 7. Ndrepepa G; Braun S; Tada T; King L; Cassese S; Fusaro M; Keta D; Kastrati A; Schmidt R. Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. *Indian J Med Res* 2014;140:392-400
 8. Kufner S; Kastrati A. Drug-eluting stents for drug-eluting stent restenosis: stick with the old or switch to a new one? *Coron Artery Dis* 2014;25:633-5
 9. Cassese S; Byrne RA; Schulz S; Hoppman P; Kreutzer J; Feuchtenberger A; Ibrahim T; Ott I; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A. Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. *Eur Heart J* 2015;36:94-9
 10. Kasel AM; Shivaraju A; Schneider S; Krapf S; Oertel F; Burgdorf C; Ott I; Sumer C; Kastrati A; von Scheidt W; Thilo C. Standardized methodology for transfemoral transcatheter aortic valve replacement with the Edwards Sapien XT valve under fluoroscopy guidance. *J Invasive Cardiol* 2014;26:451-61
 11. Windecker S; Kolh P; Alfonso F; Collet JP; Cremer J; Falk V; Filippatos G; Hamm C; Head SJ; Juni P; Kappetein AP; Kastrati A; Knuuti J; Landmesser U; Laufer G; Neumann FJ; Richter DJ; Schauerte P; Sousa Uva M; Stefanini GG; Taggart DP; Torracca L; Valgimigli M; Wijns W; Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. *EuroIntervention* 2015;10:1024-94
 12. Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A.

- Prasugrelvs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. *Thromb Haemost* 2014;112:1190-7
13. Kolh P; Windecker S; Alfonso F; Collet JP; Cremer J; Falk V; Filippatos G; Hamm C; Head SJ; Juni P; Kappetein AP; Kastrati A; Knuuti J; Landmesser U; Laufer G; Neumann FJ; Richter DJ; Schauerte P; Sousa Uva M; Stefanini GG; Taggart DP; Torracca L; Valgimigli M; Wijns W; Witkowski A; Guidelines ESCCfP; Zamorano JL; Achenbach S; Baumgartner H; Bax JJ; Bueno H; Dean V; Deaton C; Erol C; Fagard R; Ferrari R; Hasdai D; Hoes AW; Kirchhof P; Knuuti J; Kolh P; Lancellotti P; Linhart A; Nihoyannopoulos P; Piepoli MF; Ponikowski P; Sirnes PA; Tamargo JL; Tendera M; Torbicki A; Wijns W; Windecker S; Committee ECG; Sousa Uva M; Achenbach S; Pepper J; Anyanwu A; Badimon L; Bauersachs J; Baumbach A; Beygui F; Bonaros N; De Carlo M; Deaton C; Dobrev D; Dunning J; Eeckhout E; Gielen S; Hasdai D; Kirchhof P; Luckraz H; Mahrholdt H; Montalescot G; Paparella D; Rastan AJ; Sanmartin M; Sergeant P; Silber S; Tamargo J; ten Berg J; Thiele H; van Geuns RJ; Wagner HO; Wassmann S; Wendler O; Zamorano JL. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur J Cardiothorac Surg* 2014;46:517-92
 14. Authors/Task Force m; Windecker S; Kolh P; Alfonso F; Collet JP; Cremer J; Falk V; Filippatos G; Hamm C; Head SJ; Juni P; Kappetein AP; Kastrati A; Knuuti J; Landmesser U; Laufer G; Neumann FJ; Richter DJ; Schauerte P; Sousa Uva M; Stefanini GG; Taggart DP; Torracca L; Valgimigli M; Wijns W; Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;35:2541-619
 15. Mayer K; Bernlochner I; Braun S; Schulz S; Orban M; Morath T; Cala L; Hoppmann P; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. *J Am Coll Cardiol* 2014;64:863-71
 16. Guerra E; Byrne RA; Kastrati A. Pharmacological inhibition of coronary restenosis: systemic and local approaches. *Expert Opin Pharmacother* 2014;15:2155-71
 17. Cassese S; Byrne RA; Laugwitz KL; Schunkert H; Berger PB; Kastrati A. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. *EuroIntervention* 2014;
 18. D'Ascenzo F; Cerrato E; Appleton D; Moretti C; Calcagno A; Abouzaki N; Vetrovec G; Lhermusier T; Carrie D; Das Neves B; Escaned J; Cassese S; Kastrati A; Chinaglia A; Belli R; Capodanno D; Tamburino C; Santilli F; Parodi G; Vachiat A; Manga P; Vignali L; Mancone M; Sardella G; Fedele F; DiNicolantonio JJ; Omede P; Bonora S; Gaita F; Abbate A; Zoccai GB; Percutaneous coronary i; surgical revascularization in HIVDSI. Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. *Thromb Res* 2014;134:558-64
 19. Hoppmann P; Koch W; Laugwitz KL; Kastrati A. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. *Coron Artery Dis* 2014;25:658-64
 20. Cassese S; Fusaro M; Byrne RA; Tada T; Hoppmann P; Joner M; Laugwitz KL; Schunkert H; Kastrati A. Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. *Int J Cardiol* 2014;175:484-91
 21. Kasel AM; Cassese S; Ischinger T; Leber A; Antoni D; Riess G; Vogel J; Kastrati A; Eichinger W; Hoffmann E. A prospective, non-randomized comparison of SAPIEN XT and CoreValve

- implantation in two sequential cohorts of patients with severe aortic stenosis. *Am J Cardiovasc Dis* 2014;4:87-99
22. Langhans B; Nadjiri J; Jahnichen C; Kastrati A; Martinoff S; Hadamitzky M. Reproducibility of area at risk assessment in acute myocardial infarction by T1- and T2-mapping sequences in cardiac magnetic resonance imaging in comparison to Tc99m-sestamibi SPECT. *Int J Cardiovasc Imaging* 2014;30:1357-63
 23. Shivaraju A; Ott I; Kastrati A; Kasel AM. Valve-in-valve transfemoral TAVR: Sapien 3 valve within a failed core valve bioprosthesis. *Eur Heart J* 2014;35:2684
 24. Xhepa E; Tada T; Cassese S; King L; Ott I; Fusaro M; Kastrati A; Byrne RA. Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. *Indian Heart J* 2014;66:345-9
 25. Windecker S; Stortecky S; Stefanini GG; da Costa BR; Rutjes AW; Di Nisio M; Silletta MG; Maione A; Alfonso F; Clemmensen PM; Collet JP; Cremer J; Falk V; Filippatos G; Hamm C; Head S; Kappetein AP; Kastrati A; Knuuti J; Landmesser U; Laufer G; Neumann FJ; Richter D; Schauerte P; Sousa Uva M; Taggart DP; Torracca L; Valgimigli M; Wijns W; Witkowski A; Kolh P; Juni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ* 2014;348:g3859
 26. Xhepa E; Byrne RA; Schulz S; Helde S; Gewalt S; Cassese S; Linhardt M; Ibrahim T; Mehilli J; Hoppe K; Grupp K; Kufner S; Bottiger C; Hoppmann P; Burgdorf C; Fusaro M; Ott I; Schneider S; Hengstenberg C; Schunkert H; Laugwitz KL; Kastrati A; investigators I-C. Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial. *EuroIntervention* 2014;10:198-203
 27. Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tolg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A; Bavarian Reperfusion Alternatives Evaluation I. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. *Eur Heart J* 2014;35:2285-94
 28. Ndrepepa G; Guerra E; Schulz S; Hoppmann P; Laugwitz KL; Kastrati A. Correlates of poor outcome among patients with bleeding after coronary interventions. *Coron Artery Dis* 2014;25:456-62
 29. Guerra E; Hadamitzky M; Ndrepepa G; Bauer C; Ibrahim T; Ott I; Laugwitz KL; Schunkert H; Kastrati A. Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study. *Int J Cardiovasc Imaging* 2014;30:1087-95
 30. Cassese S; Desch S; Kastrati A; Byrne RA; King L; Tada T; Lauer B; Schomig A; Thiele H; Pache J. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials. *Rev Esp Cardiol (Engl Ed)* 2013;66:435-42
 31. Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. *Thromb Haemost* 2014;112:342-51
 32. Ndrepepa G; Schulz S; Neumann FJ; Laugwitz KL; Richardt G; Byrne RA; Pohler A; Kastrati A; Pache J. Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. *EuroIntervention* 2014;10:83-9
 33. Dzijan-Horn M; Langwieser N; Groha P; Bradaric C; Linhardt M; Bottiger C; Byrne RA; Steppich B; Koppa T; Godel J; Hadamitzky M; Ott I; von Beckerath N; Kastrati A; Laugwitz KL; Ibrahim T. Safety and efficacy of a potential treatment algorithm by using manual compression repair and

ultrasound-guided thrombin injection for the management of iatrogenic femoral artery pseudoaneurysm in a large patient cohort. *Circ Cardiovasc Interv* 2014;7:207-15

34. Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A; Intracoronary S; Angiographic Results: Drug Eluting Stents for In-Stent Restenosis I. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. *Cardiovasc Revasc Med* 2014;15:69-75
35. Fiedler KA; Byrne RA; Schulz S; Sibbing D; Mehilli J; Ibrahim T; Maeng M; Laugwitz KL; Kastrati A; Sarafoff N. Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. *Am Heart J* 2014;167:459-465 e1
36. Schulz S; Richardt G; Laugwitz KL; Mehran R; Gershlick AH; Morath T; Mayer K; Neudecker J; Tolg R; Ibrahim T; Hauschke D; Braun D; Schunkert H; Kastrati A; Mehilli J; Bavarian Reperfusion Alternatives Evaluation I. Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. *Clin Cardiol* 2014;37:270-6
37. Fiedler KA; Mehilli J; Kufner S; Schlichting A; Ibrahim T; Sibbing D; Ott I; Schunkert H; Laugwitz KL; Kastrati A; Schulz S. Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. *Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION. Thromb Haemost* 2014;111:1041-9
38. Alfonso F; Byrne RA; Rivero F; Kastrati A. Current treatment of in-stent restenosis. *J Am Coll Cardiol* 2014;63:2659-73
39. Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. *Cardiovasc Revasc Med* 2014;15:131-6
40. de Waha A; King LA; Stefanini GG; Byrne RA; Serruys PW; Meier B; Juni P; Kastrati A; Windecker S. Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. *EuroIntervention* 2015;10:1425-31
41. Ndrepepa G; Kastrati A. Bleeding complications in patients undergoing percutaneous coronary interventions: current status and perspective. *Coron Artery Dis* 2014;25:247-57
42. Tada T; Kastrati A; Byrne RA; Schuster T; Cuni R; King LA; Cassese S; Joner M; Pache J; Massberg S; Schomig A; Mehilli J. Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. *Int J Cardiovasc Imaging* 2014;30:495-504
43. Mayer K; Orban M; Bernlochner I; Braun S; Schulz S; Gross L; Hadamitzky M; Schunkert H; Laugwitz KL; Massberg S; Kastrati A; Sibbing D. Predictors of antiplatelet response to prasugrel during maintenance treatment. *Platelets* 2015;26:53-8
44. Schulz S; Angiolillo DJ; Antoniucci D; Bernlochner I; Hamm C; Jaitner J; Laugwitz KL; Mayer K; von Merzljak B; Morath T; Neumann FJ; Richardt G; Ruf J; Schomig G; Schühlen H; Schunkert H; Kastrati A; Intracoronary S; Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 Trial I. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. *J Cardiovasc Transl Res* 2014;7:91-100

45. Fusaro M; Cassese S; Ndrepepa G; Tepe G; King L; Ott I; Nerad M; Schunkert H; Kastrati A. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. *JACC Cardiovasc Interv* 2013;6:1284-93
46. Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. *JACC Cardiovasc Interv* 2013;6:1267-74
47. Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A; Investigators I-LMS. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease. *JACC Cardiovasc Interv* 2014;7:29-36
48. Braun D; Lesevic H; Orban M; Michalk F; Barthel P; Hoppe K; Sonne C; Pache J; Mehilli J; Kastrati A; Hausleiter J; Massberg S. Percutaneous edge-to-edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation. *Catheter Cardiovasc Interv* 2014;84:137-46
49. Cassese S; Byrne RA; Tada T; Piniack S; Joner M; Ibrahim T; King LA; Fusaro M; Laugwitz KL; Kastrati A. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. *Heart* 2014;100:153-9
50. Hadamitzky M; Langhans B; Hausleiter J; Sonne C; Byrne RA; Mehilli J; Kastrati A; Schomig A; Martinoff S; Ibrahim T. Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi. *Eur Heart J Cardiovasc Imaging* 2014;15:216-25
51. Byrne RA; Joner M; Alfonso F; Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. *Nat Rev Cardiol* 2014;11:13-23
52. Byrne RA; Kastrati A. Drug-eluting stent trials: too much non-inferiority, too little progress? *Lancet* 2014;383:386-8
53. Leibundgut G; Pache J; Schulz S; Berger PB; Ferenc M; Gick M; Mehilli J; Kastrati A; Neumann FJ. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non ST-segment elevation myocardial infarction. *J Interv Cardiol* 2013;26:623-9
54. Ndrepepa G; Cassese S; Braun S; Fusaro M; King L; Tada T; Schomig A; Kastrati A; Schmidt R. A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. *Nutr Metab Cardiovasc Dis* 2013;23:1195-201
55. Ndrepepa G; Neumann FJ; Cassese S; Fusaro M; Ott I; Schulz S; Hoppmann P; Richardt G; Laugwitz KL; Schunkert H; Kastrati A. Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. *Clin Res Cardiol* 2014;103:49-56
56. Ndrepepa G; Neumann FJ; Schulz S; Fusaro M; Cassese S; Byrne RA; Richardt G; Laugwitz KL; Kastrati A. Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. *Catheter Cardiovasc Interv* 2014;83:182-9

2013

1. Ndrepepa G; Schulz S; Neumann FJ; Byrne RA; Hoppmann P; Cassese S; Ott I; Fusaro M; Ibrahim T; Tada T; Richardt G; Laugwitz KL; Schunkert H; Kastrati A. Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. *Am Heart J* 2013;166:534-40

2. Stefanini GG; Baber U; Windecker S; Morice MC; Sartori S; Leon MB; Stone GW; Serruys PW; Wijns W; Weisz G; Camenzind E; Steg PG; Smits PC; Kandzari D; Von Birgelen C; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Valgimigli M; Kastrati A; Chieffo A; Mehran R. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. *Lancet* 2013;382:1879-88
3. Ndrepepa G; Kastrati A. Intravenous beta-blockers in primary percutaneous coronary intervention: new hope for an old therapy. *Circulation* 2013;128:1487-9
4. de Waha A; Stefanini GG; King LA; Byrne RA; Serruys PW; Kufner S; Meier B; Juni P; Kastrati A; Windecker S. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. *Int J Cardiol* 2013;168:5162-6
5. Byrne RA; Kastrati A. Unmet aspirations--where to now for catheter thrombectomy? *N Engl J Med* 2013;369:1649-50
6. Mehilli J; Richardt G; Valgimigli M; Schulz S; Singh A; Abdel-Wahab M; Tiroch K; Pache J; Hausleiter J; Byrne RA; Ott I; Ibrahim T; Fusaro M; Seyfarth M; Laugwitz KL; Massberg S; Kastrati A; Investigators I-L-MS. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2013;62:2075-82
7. Ndrepepa G; Braun S; Cassese S; Fusaro M; King L; Kastrati A; Schmidt R. C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. *Cardiovasc Revasc Med* 2013;14:264-9
8. Verschuren JJ; Trompet S; Sampietro ML; Heijmans BT; Koch W; Kastrati A; Houwing-Duistermaat JJ; Slagboom PE; Quax PH; Jukema JW. Pathway analysis using genome-wide association study data for coronary restenosis--a potential role for the PARVB gene. *PLoS One* 2013;8:e70676
9. King LA; Kastrati A; Byrne RA. Treatment of coronary drug-eluting stent restenosis: a journey back to the future? *Expert Rev Med Devices* 2013;10:423-7
10. Fusaro M; Cassese S; Ndrepepa G; King LA; Tada T; Ott I; Kastrati A. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. *Int J Cardiol* 2013;168:4002-9
11. Ndrepepa G; Neumann FJ; Richardt G; Schulz S; Tolg R; Stoyanov KM; Gick M; Ibrahim T; Fiedler KA; Berger PB; Laugwitz KL; Kastrati A. Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. *Circ Cardiovasc Interv* 2013;6:354-61
12. Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schomig A; Kastrati A. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial. *Catheter Cardiovasc Interv* 2013;82:E769-76
13. Byrne RA; Cassese S; Windisch T; King LA; Joner M; Tada T; Mehilli J; Pache J; Kastrati A. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. *EuroIntervention* 2013;9:797-802
14. Ndrepepa G; Fusaro M; King L; Cassese S; Tada T; Schomig A; Kastrati A. Statin pretreatment and presentation patterns in patients with coronary artery disease. *Cardiol J* 2013;20:52-8
15. Malle C; Tada T; Steigerwald K; Ughi GJ; Schuster T; Nakano M; Massberg S; Jehle J; Guagliumi G; Kastrati A; Virmani R; Byrne RA; Joner M. Tissue characterization after drug-eluting stent implantation using optical coherence tomography. *Arterioscler Thromb Vasc Biol* 2013;33:1376-83
16. Mehilli J; Neumann FJ; Ndrepepa G; King L; Schulz S; Maimon Rodrigues da Cunha F; Jochheim D; Byrne RA; Hausleiter J; Ott I; Massberg S; Kastrati A; Pache J. Sex-related effectiveness of

- bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. *Am Heart J* 2013;165:537-43
17. Sarafoff N; Martischnig A; Wealer J; Mayer K; Mehilli J; Sibbing D; Kastrati A. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. *J Am Coll Cardiol* 2013;61:2060-6
 18. Kasel AM; Cassese S; Leber AW; von Scheidt W; Kastrati A. Fluoroscopy-guided aortic root imaging for TAVR: "follow the right cusp" rule. *JACC Cardiovasc Imaging* 2013;6:274-5
 19. Kasel AM; Cassese S; Bleiziffer S; Amaki M; Hahn RT; Kastrati A; Sengupta PP. Standardized imaging for aortic annular sizing: implications for transcatheter valve selection. *JACC Cardiovasc Imaging* 2013;6:249-62
 20. Hadamitzky M; Langhans B; Hausleiter J; Sonne C; Kastrati A; Martinoff S; Schomig A; Ibrahim T. The assessment of area at risk and myocardial salvage after coronary revascularization in acute myocardial infarction: comparison between CMR and SPECT. *JACC Cardiovasc Imaging* 2013;6:358-69
 21. Schulz S; Kastrati A; Ferenc M; Massberg S; Birkmeier KA; Laugwitz KL; Kufner S; Gick M; Dommasch M; Schuhlen H; Schomig A; Berger PB; Mehilli J; Neumann FJ; Intracoronary S; Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4 Trial I. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. *EuroIntervention* 2013;9:430-6
 22. Schulz S; Kastrati A. Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. *Eur Heart J* 2013;34:872-4
 23. Kastrati A; Neumann FJ. SORT OUT V: a new episode in the DES wars. *Lancet* 2013;381:609-11
 24. Braun D; Orban M; Michalk F; Barthel P; Hoppe K; Sonne C; Lesevic H; Pache J; Mehilli J; Kastrati A; Hausleiter J; Massberg S. Three-dimensional transoesophageal echocardiography for the assessment of clip attachment to the leaflets in percutaneous edge-to-edge repair of the mitral valve. *EuroIntervention* 2013;8:1379-87
 25. Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schomig A; Kastrati A. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. *Cardiovasc Revasc Med* 2013;14:84-9
 26. Rivera NV; Carreras-Torres R; Roncarati R; Viviani-Anselmi C; De Micco F; Mezzelani A; Koch W; Hoppmann P; Kastrati A; Stewart AF; Chen L; Roberts R; Karssen LC; Amin N; Trimarco V; Izzo R; Iaccarino G; Condorelli G; Puca AA; Pagnotta P; Airoidi F; Trimarco B; van Duijn CM; Condorelli G; Briguori C. Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. *BMC Med Genet* 2013;14:11
 27. Bernlochner I; Mayer K; Morath T; Orban M; Schulz S; Schomig A; Braun S; Kastrati A; Sibbing D. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. *Thromb Haemost* 2013;109:517-24
 28. Ndrepepa G; Braun S; King L; Fusaro M; Keta D; Cassese S; Tada T; Schomig A; Kastrati A. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. *Am J Cardiol* 2013;111:804-10
 29. Ndrepepa G; Braun S; King L; Fusaro M; Tada T; Cassese S; Hadamitzky M; Haase HU; Schomig A; Kastrati A. Uric acid and prognosis in angiography-proven coronary artery disease. *Eur J Clin Invest* 2013;43:256-66
 30. Koch W; Mueller JC; Schrepf M; Wolferstetter H; Kirchhofer J; Schomig A; Kastrati A. Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene. *Ann Hum Genet* 2013;77:47-55

31. Hyseni A; Roest M; Braun SL; Barendrecht AD; de Groot PG; Ndrepepa G; Kastrati A. Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. *Thromb Res* 2013;131:198-203
32. Tada T; Byrne RA; Cassese S; King L; Schulz S; Mehilli J; Schomig A; Kastrati A. Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. *Am Heart J* 2013;165:80-6
33. Byrne RA; Neumann FJ; Mehilli J; Piniack S; Wolff B; Tiroch K; Schulz S; Fusaro M; Ott I; Ibrahim T; Hausleiter J; Valina C; Pache J; Laugwitz KL; Massberg S; Kastrati A; investigators I-D. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet* 2013;381:461-7
34. Byrne RA; Cassese S; Linhardt M; Kastrati A. Vascular access and closure in coronary angiography and percutaneous intervention. *Nat Rev Cardiol* 2013;10:27-40
35. Ndrepepa G; King L; Cassese S; Fusaro M; Tada T; Schomig A; Kastrati A. Prehospital statin therapy and one-year mortality in patients with stable coronary artery disease undergoing percutaneous coronary intervention. *Eur J Intern Med* 2013;24:145-50
36. Cassese S; Byrne RA; Tada T; King LA; Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. *Eur Heart J* 2012;33:3078-87
37. Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schomig A; Kastrati A; Stone GW. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials. *Circ Cardiovasc Interv* 2012;5:705-12
38. Orban M; Joner M; Riegger J; Steigerwald K; Tada T; Ibrahim T; Laugwitz KL; Byrne RA; Kastrati A; Massberg S. Time does not heal all wounds: very late stent thrombosis eight years after implantation of a sirolimus-eluting stent due to positive remodelling, saccular evaginations and marked vascular inflammation. *EuroIntervention* 2013;9:412-3
39. Bernlochner I; Mayer K; Morath T; Braun S; Schulz S; Schomig A; Koch W; Kastrati A; Sibbing D. High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring. *Platelets* 2013;24:500-2
40. Bernlochner I; Morath T; Brown PB; Zhou C; Baker BA; Gupta N; Jakubowski JA; Winters KJ; Schomig A; Kastrati A; Sibbing D. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. *Platelets* 2013;24:15-25

2012

1. Sibbing D; Hochholzer W; Kastrati A. Influence of smoking on treatment with clopidogrel. *JAMA* 2012;308:1322-3; author reply 1323-4
2. Kastrati A. New anti-platelet agents: the end of resistance? *Thromb Res* 2012;130 Suppl 1:S53-5
3. Byrne RA; Joner M; Tada T; Kastrati A. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. *Minerva Cardioangiolog* 2012;60:473-89
4. Ndrepepa G; Braun S; King L; Cassese S; Tada T; Fusaro M; Hadamitzky M; Haase HU; Schomig A; Kastrati A. Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease. *Clin Sci (Lond)* 2013;124:259-68

5. Byrne RA; Kastrati A; Hausleiter J. The battle against stent thrombosis--to protect and to serve. *Lancet* 2012;380:1365-7
6. Cassese S; Ndrepepa G; King LA; Tada T; Fusaro M; Kastrati A. Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison. *Heart* 2012;98:1632-40
7. Task Force on the management of ST-segment elevation myocardial infarction of the European Society of Cardiology; Steg PG; James SK; Atar D; Badano LP; Blomstrom-Lundqvist C; Borger MA; Di Mario C; Dickstein K; Ducrocq G; Fernandez-Aviles F; Gershlick AH; Giannuzzi P; Halvorsen S; Huber K; Juni P; Kastrati A; Knuuti J; Lenzen MJ; Mahaffey KW; Valgimigli M; van 't Hof A; Widimsky P; Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;33:2569-619
8. Cassese S; Kastrati A. Not all drug-eluting balloons are equally good for patients, not all patients are equally suitable for drug-eluting balloons. *EuroIntervention* 2012;8:417-21
9. Cassese S; Kastrati A. New-generation drug-eluting stents for patients with myocardial infarction. *JAMA* 2012;308:814-5
10. Cassese S; Byrne RA; Ott I; Ndrepepa G; Nerad M; Kastrati A; Fusaro M. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. *Circ Cardiovasc Interv* 2012;5:582-9
11. Sibbing D; Bernlochner I; Schulz S; Massberg S; Schomig A; Mehilli J; Kastrati A. The impact of smoking on the antiplatelet action of clopidogrel in non-ST-elevation myocardial infarction patients: results from the ISAR-REACT 4 platelet substudy. *J Thromb Haemost* 2012;10:2199-202
12. Cassese S; de Waha A; Ndrepepa G; Ranftl S; King L; Schomig A; Kastrati A. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction without cardiogenic shock. A meta-analysis of randomized trials. *Am Heart J* 2012;164:58-65 e1
13. Ndrepepa G; Tada T; Fusaro M; Cassese S; King L; Hadamitzky M; Haase HU; Schomig A; Kastrati A; Pache J. Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease. *Clin Res Cardiol* 2012;101:1003-11
14. Ndrepepa G; Braun S; King L; Hadamitzky M; Haase HU; Birkmeier KA; Schomig A; Kastrati A. Association of uric acid with mortality in patients with stable coronary artery disease. *Metabolism* 2012;61:1780-6
15. Kastrati A; Mehilli J; Dirschinger J; Dotzer F; Schuhlen H; Neumann FJ; Fleckenstein M; Pfafferott C; Seyfarth M; Schomig A. [Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial]. *Vestn Rentgenol Radiol* 2012;52-60
16. Sibbing D; Bernlochner I; Schulz S; Massberg S; Schomig A; Mehilli J; Kastrati A. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. *J Am Coll Cardiol* 2012;60:369-77
17. Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. *Platelets* 2012;23:395-8
18. Tada T; Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Byrne RA; Kastrati A; Kadota K; Iwabuchi M; Shizuta S; Tazaki J; Shiomi H; Abe M; Ehara N; Mizoguchi T; Mitsuoka H; Inada T; Araki M; Kaburagi S; Taniguchi R; Eizawa H; Nakano A; Suwa S; Takizawa A; Nohara R; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T; Investigators CR-KPCRC-. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark

analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. *Circ Cardiovasc Interv* 2012;5:381-91

19. Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Muller U; Richardt G; Jakubowski JA; Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. *J Am Coll Cardiol* 2012;59:2159-64
20. Byrne RA; Kastrati A. No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. *Expert Rev Cardiovasc Ther* 2012;10:429-32
21. Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Juni P; Schomig A; Windecker S; Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. *Eur Heart J* 2012;33:1214-22
22. King L; Byrne RA; Mehilli J; Schomig A; Kastrati A; Pache J. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. *Catheter Cardiovasc Interv* 2013;81:E23-8
23. de Waha A; Cassese S; Park DW; Burzotta F; Byrne RA; Tada T; King LA; Park SJ; Schomig A; Kastrati A. Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. *Clin Res Cardiol* 2012;101:461-7
24. Cassese S; Tada T; Kastrati A. Lost contact with vessel wall, signed contract with stent thrombosis? *Eur Heart J* 2012;33:1305-8
25. Ndrepepa G; Schuster T; Hadamitzky M; Byrne RA; Mehilli J; Neumann FJ; Richardt G; Schulz S; Laugwitz KL; Massberg S; Schomig A; Kastrati A. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. *Circulation* 2012;125:1424-31
26. Cortese B; Piti A; Kastrati A; Sibbing D. In the bivalirudin era, are we still looking for a potent antiplatelet agent? *Curr Vasc Pharmacol* 2012;10:476-8
27. Ndrepepa G; Braun S; Haase HU; Schulz S; Ranftl S; Hadamitzky M; Mehilli J; Schomig A; Kastrati A. Prognostic value of uric acid in patients with acute coronary syndromes. *Am J Cardiol* 2012;109:1260-5
28. Stein A; Mohr F; Laux M; Thieme S; Lorenz B; Cetindis M; Hackl J; Groha P; Demetz G; Schulz S; Mehilli J; Schomig A; Kastrati A; Ott I. Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. *Thromb Haemost* 2012;107:769-74
29. Tada T; Byrne RA; Kastrati A. A case where the principle of "one question, one answer" may work better. *Am Heart J* 2012;163:133-5
30. Jaitner J; Morath T; Byrne RA; Braun S; Gebhard D; Bernlochner I; Schulz S; Mehilli J; Schomig A; Koch W; Kastrati A; Sibbing D. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. *Circ Cardiovasc Interv* 2012;5:82-8, S1-2
31. Ndrepepa G; Alger P; Kufner S; Mehilli J; Schomig A; Kastrati A. ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. *Cardiol J* 2012;19:61-9

2011

1. Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schomig A; Berger PB; Mehilli J; Investigators I-RT. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. *N Engl J Med* 2011;365:1980-9
2. Byrne RA; Kastrati A. Lesions in small coronary vessels disease: should drug-coated balloons replace drug-eluting stents as the treatment of choice? *EuroIntervention* 2011;7 Suppl K:K47-52
3. Kastrati A; Byrne RA; Schulz S. Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation? *JACC Cardiovasc Interv* 2011;4:1129-32
4. Koch W; Wolferstetter H; Schatke A; Schomig A; Kastrati A. Interleukin 18 gene variation and risk of acute myocardial infarction. *Cytokine* 2011;56:786-91
5. Pare G; Eikelboom JW; Sibbing D; Bernlochner I; Kastrati A. Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv* 2011;4:514-21; discussion 521
6. Sibbing D; Bernlochner I; Kastrati A; Pare G; Eikelboom JW. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. *Circ Cardiovasc Interv* 2011;4:505-13; discussion 513
7. Kufner S; de Waha A; Tomai F; Park SW; Lee SW; Lim DS; Kim MH; Galloe AM; Maeng M; Briguori C; Dibra A; Schomig A; Kastrati A. A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. *Am Heart J* 2011;162:740-7
8. Baber U; Mehran R; Sharma SK; Brar S; Yu J; Suh JW; Kim HS; Park SJ; Kastrati A; de Waha A; Krishnan P; Moreno P; Sweeny J; Kim MC; Suleman J; Pyo R; Wiley J; Kovacic J; Kini AS; Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. *J Am Coll Cardiol* 2011;58:1569-77
9. Byrne RA; Kastrati A; Massberg S; Wieczorek A; Laugwitz KL; Hadamitzky M; Schulz S; Pache J; Fusaro M; Hausleiter J; Schomig A; Mehilli J; Investigators I-T. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. *J Am Coll Cardiol* 2011;58:1325-31
10. Hochholzer W; Trenk D; Mega JL; Morath T; Stratz C; Valina CM; O'Donoghue ML; Bernlochner I; Contant CF; Guo J; Sabatine MS; Schomig A; Neumann FJ; Kastrati A; Wiviott SD; Sibbing D. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. *Am Heart J* 2011;162:518-26 e5
11. Sampietro ML; Trompet S; Verschuren JJ; Talens RP; Deelen J; Heijmans BT; de Winter RJ; Tio RA; Doevendans PA; Ganesh SK; Nabel EG; Westra HJ; Franke L; van den Akker EB; Westendorp RG; Zwinderman AH; Kastrati A; Koch W; Slagboom PE; de Knijff P; Jukema JW. A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. *Hum Mol Genet* 2011;20:4748-57
12. Ndrepepa G; Kastrati A. Need for critical reappraisal of intra-aortic balloon counterpulsation. *JAMA* 2011;306:1376-7
13. Bernlochner I; Byrne RA; Kastrati A; Sibbing D. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. *Expert Rev Cardiovasc Ther* 2011;9:999-1014
14. Mehilli J; Pache J; Abdel-Wahab M; Schulz S; Byrne RA; Tiroch K; Hausleiter J; Seyfarth M; Ott I; Ibrahim T; Fusaro M; Laugwitz KL; Massberg S; Neumann FJ; Richardt G; Schomig A; Kastrati A; Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts I. Drug-

- eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. *Lancet* 2011;378:1071-8
15. Kastrati A; Massberg S; Ndrepepa G. Is diabetes the achilles' heel of limus-eluting stents? *Circulation* 2011;124:869-72
 16. Ndrepepa G; Schomig A; Kastrati A. Efficacy of reperfusion with primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction. *Clin Res Cardiol* 2011;100:1047-8
 17. de Waha A; Dibra A; Byrne RA; Ndrepepa G; Mehilli J; Fusaro M; Laugwitz KL; Massberg S; Schomig A; Kastrati A. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. *Circ Cardiovasc Interv* 2011;4:371-7
 18. Massberg S; Byrne RA; Kastrati A; Schulz S; Pache J; Hausleiter J; Ibrahim T; Fusaro M; Ott I; Schomig A; Laugwitz KL; Mehilli J; Intracoronary S; Angiographic Results: Test Efficacy of S; ProbucoL-Eluting Versus Zotarolimus- Eluting Stents I. Polymer-free sirolimus- and probucoL-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and ProbucoL-eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. *Circulation* 2011;124:624-32
 19. Roos M; Schuster T; Ndrepepa G; Baumann M; Lutz J; Braun S; Martinof S; Schomig A; Heemann U; Kastrati A; Hausleiter J. Association of midregional proadrenomedullin with coronary artery stenoses, soft atherosclerotic plaques and coronary artery calcium. *Heart Vessels* 2012;27:352-9
 20. Sibbing D; Byrne RA; Kastrati A. Role of platelet function testing in clinical practice: current concepts and future perspectives. *Curr Drug Targets* 2011;12:1836-47
 21. Ndrepepa G; Braun S; Schulz S; Mehilli J; Schomig A; Kastrati A. High-sensitivity troponin T level and angiographic severity of coronary artery disease. *Am J Cardiol* 2011;108:639-43
 22. Cortese B; Bertoletti A; De Matteis S; Danzi GB; Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. *Int J Cardiol* 2012;161:73-82
 23. Ndrepepa G; Alger P; Fusaro M; Kufner S; Seyfarth M; Keta D; Mehilli J; Schomig A; Kastrati A. Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. *EuroIntervention* 2011;7:128-35
 24. Katritsis DG; Efsthathopoulos EP; Pantos I; Tzanalariidou E; De Waha A; Siontis GC; Toutouzas K; Redwood S; Kastrati A; Stefanadis C. Ruptured versus stable plaques in human coronary arteries. *Coron Artery Dis* 2011;22:345-51
 25. Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schomig A; Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. *Eur Heart J* 2011;32:1605-13
 26. Koch W; Turk S; Erl A; Hoppmann P; Pfeufer A; King L; Schomig A; Kastrati A. The chromosome 9p21 region and myocardial infarction in a European population. *Atherosclerosis* 2011;217:220-6
 27. Sibbing D; Byrne RA; Bernlochner I; Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. *Thromb Haemost* 2011;106:191-202
 28. Ndrepepa G; King L; Kastrati A. More deserved focus on diabetic patients. *Circ Cardiovasc Interv* 2011;4:115-7
 29. Ndrepepa G; Braun S; Schulz S; Byrne RA; Pache J; Mehilli J; Schomig A; Kastrati A. Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. *Clin Chim Acta* 2011;412:1350-6
 30. Ndrepepa G; Braun S; Schulz S; Fusaro M; Keta D; Pache J; Seyfarth M; Mehilli J; Schomig A; Kastrati A. Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. *Eur J Clin Invest* 2011;41:1054-62

31. Kufner S; Massberg S; Dommasch M; Byrne RA; Tiroch K; Ranftl S; Fusaro M; Schomig A; Kastrati A; Mehilli J; Intracoronary S; Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents Trial I. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. *Catheter Cardiovasc Interv* 2011;78:161-6
32. Sarafoff N; Neumann L; Morath T; Bernlochner I; Mehilli J; Schomig A; Kastrati A; Sibbing D. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. *Am Heart J* 2011;161:605-10
33. de Boer SP; Barnes EH; Westerhout CM; Simes RJ; Granger CB; Kastrati A; Widimsky P; de Boer MJ; Zijlstra F; Boersma E. High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. *Am Heart J* 2011;161:500-507 e1
34. Schulz S; Mehilli J; Ndrepepa G; Dotzer F; Dommasch M; Kufner S; Birkmeier KA; Tiroch K; Byrne RA; Schomig A; Kastrati A. Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. *Clin Res Cardiol* 2011;100:691-9
35. Kastrati A; Byrne R. New roads, new ruts: lessons from drug-eluting stent restenosis. *JACC Cardiovasc Interv* 2011;4:165-7
36. Khattab AA; Ndrepepa G; Schulz S; Neumann FJ; Mehilli J; Buttner HJ; Pache J; Seyfarth M; Dirschinger J; Kastrati A; Berger PB; Schomig A; Richardt G. Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. *Clin Res Cardiol* 2011;100:579-85
37. Koch W; Schatke A; Wolferstetter H; Mueller JC; Schomig A; Kastrati A. Extended evidence for association between the melanoma inhibitory activity 3 gene and myocardial infarction. *Thromb Haemost* 2011;105:670-5
38. Sibbing D; Pfeufer A; Perisic T; Mannes AM; Fritz-Wolf K; Unwin S; Sinner MF; Gieger C; Gloeckner CJ; Wichmann HE; Kremmer E; Schafer Z; Walch A; Hinterseer M; Nabauer M; Kaab S; Kastrati A; Schomig A; Meitinger T; Bornkamm GW; Conrad M; von Beckerath N. Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy. *Eur Heart J* 2011;32:1121-33
39. Banerjee S; Weideman RA; Weideman MW; Little BB; Kelly KC; Gunter JT; Tortorice KL; Shank M; Cryer B; Reilly RF; Rao SV; Kastrati A; de Lemos JA; Brilakis ES; Bhatt DL. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. *Am J Cardiol* 2011;107:871-8
40. de Waha A; Dibra A; Kufner S; Baumgart D; Sabate M; Maresta A; Schomig A; Kastrati A. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. *Clin Res Cardiol* 2011;100:561-70
41. Ndrepepa G; Braun S; Mehilli J; Birkmeier KA; Byrne RA; Ott I; Hosl K; Schulz S; Fusaro M; Pache J; Hausleiter J; Laugwitz KL; Massberg S; Seyfarth M; Schomig A; Kastrati A. Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. *Am Heart J* 2011;161:68-75
42. Steppich BA; Demetz G; Schulz S; von Wedel J; Pogatsa-Murray G; Braun SL; Stein A; Kastrati A; Schomig A; Ott I. Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. *Thromb Res* 2011;127:119-21
43. Ndrepepa G; Braun S; Schomig A; Kastrati A. Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. *Clin Res Cardiol* 2011;100:327-33

44. Byrne RA; Ndrepepa G; Braun S; Tiroch K; Mehilli J; Schulz S; Schomig A; Kastrati A. Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Am J Cardiol* 2010;106:1212-7
45. Jaitner J; Stegherr J; Morath T; Braun S; Bernlochner I; Schomig A; Kastrati A; Sibbing D. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. *Thromb Haemost* 2011;105:107-12
46. Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *JAMA* 2010;304:1821-30
47. Hadamitzky M; Distler R; Meyer T; Hein F; Kastrati A; Martinoff S; Schomig A; Hausleiter J. Prognostic value of coronary computed tomographic angiography in comparison with calcium scoring and clinical risk scores. *Circ Cardiovasc Imaging* 2011;4:16-23
48. Mehilli J; Tiroch K; Kastrati A. [Recanalization of chronic total coronary occlusion: indications and results]. *Dtsch Med Wochenschr* 2010;135:1931-5
49. Bernlochner I; Steinhubl S; Braun S; Morath T; Jaitner J; Stegherr J; Mehilli J; von Beckerath N; Schomig A; Kastrati A; Sibbing D. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. *Thromb Haemost* 2010;104:1193-200
50. Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schomig A; Kastrati A. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. *Am Heart J* 2010;160:506-12
51. Birkmeier KA; Kastrati A; Byrne RA; Holle H; Schulz S; Tiroch K; Kufner S; Massberg S; Laugwitz KL; Schomig A; Mehilli J. Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. *Catheter Cardiovasc Interv* 2011;77:494-501
52. von Steinburg SP; Klein E; Langwieser N; Kastrati A; Schneider KT; Zohlnhofer D. Coronary stenting after myocardial infarction during twin pregnancy--a case report. *Hypertens Pregnancy* 2011;30:485-9

2010

1. Schulz S; Mehilli J; Neumann FJ; Schuster T; Massberg S; Valina C; Seyfarth M; Pache J; Laugwitz KL; Buttner HJ; Ndrepepa G; Schomig A; Kastrati A; Intracoronary S; Antithrombotic Regimen: Rapid Early Action for Coronary Treatment ATI. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. *Eur Heart J* 2010;31:2482-91
2. Ott I; Schulz S; Mehilli J; Fichtner S; Hadamitzky M; Hoppe K; Ibrahim T; Martinoff S; Massberg S; Laugwitz KL; Dirschinger J; Schwaiger M; Kastrati A; Schmig A; Investigators R-S. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. *Circ Cardiovasc Interv* 2010;3:408-13
3. Schulz S; Mehilli J; Schomig A; Kastrati A. ISAR--a story of trials with impact on practice. *Circ J* 2010;74:1771-8

4. Katritsis DG; Siontis GC; Kastrati A; van't Hof AW; Neumann FJ; Siontis KC; Ioannidis JP. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. *Eur Heart J* 2011;32:32-40
5. Schulz S; Sibbing D; Braun S; Morath T; Mehilli J; Massberg S; Byrne RA; Schomig A; Kastrati A. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. *Am Heart J* 2010;160:355-61
6. Kastrati A; Byrne RA; Schomig A. Is it time to jettison complex mechanical thrombectomy in favor of simple manual aspiration devices? *J Am Coll Cardiol* 2010;56:1307-9
7. Ndrepepa G; Keta D; Schulz S; Mehilli J; Birkmeier A; Neumann FJ; Schomig A; Kastrati A. Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. *Heart Vessels* 2010;25:294-8
8. Sarafoff N; Sibbing D; Sonntag U; Ellert J; Schulz S; Byrne RA; Mehilli J; Schomig A; Kastrati A. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. *Thromb Haemost* 2010;104:626-32
9. Sibbing D; Steinhubl SR; Schulz S; Schomig A; Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. *J Am Coll Cardiol* 2010;56:317-8
10. Ndrepepa G; Mehilli J; Tiroch K; Fusaro M; Kufner S; Ellert J; Goedel J; Schomig A; Kastrati A. Myocardial perfusion grade, myocardial salvage indices and long-term mortality in patients with acute myocardial infarction and full restoration of epicardial blood flow after primary percutaneous coronary intervention. *Rev Esp Cardiol* 2010;63:770-8
11. Schulz S; Birkmeier KA; Ndrepepa G; Moshage W; Dotzer F; Huber K; Dirschinger J; Seyfarth M; Schomig A; Kastrati A; Mehilli J. One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. *Clin Res Cardiol* 2010;99:795-802
12. Kastrati A; Balducci M; Di Sciascio G; Moccetti T; Bortone AS; Colombo A; Waltenberger J; Hehrlein C; Investigators MA-T. A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. *EuroIntervention* 2010;5:976-80
13. Sibbing D; Gebhard D; Koch W; Braun S; Stegherr J; Morath T; Von Beckerath N; Mehilli J; Schomig A; Schuster T; Kastrati A. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. *J Thromb Haemost* 2010;8:1685-93
14. Ndrepepa G; Tiroch K; Fusaro M; Keta D; Seyfarth M; Byrne RA; Pache J; Alger P; Mehilli J; Schomig A; Kastrati A. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. *J Am Coll Cardiol* 2010;55:2383-9
15. Tiroch KA; Byrne RA; Kastrati A. Pharmacological prevention and management of restenosis. *Expert Opin Pharmacother* 2010;11:1855-72
16. Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Piniack S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schomig A; Mehilli J; Investigators I-T-. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. *J Am Coll Cardiol* 2010;55:2536-43
17. Massberg S; Kastrati A. Is it naive to load only clopidogrel-naive patients prior to PCI? *Eur Heart J* 2010;31:1298-300
18. Koch W; Schrempf M; Erl A; Mueller JC; Hoppmann P; Schomig A; Kastrati A. 4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries. *Thromb Haemost* 2010;103:1170-80

19. Mehilli J; Byrne RA; Tiroch K; Piniack S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schomig A; Kastrati A; Investigators I-D. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. *J Am Coll Cardiol* 2010;55:2710-6
20. Dibra A; Tiroch K; Schulz S; Kelbaek H; Spaulding C; Laarman GJ; Valgimigli M; Di Lorenzo E; Kaiser C; Tierala I; Mehilli J; Campo G; Thuesen L; Vink MA; Schlij MJ; Violini R; Schomig A; Kastrati A. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. *Clin Res Cardiol* 2010;99:345-57
21. Kastrati A. Is diabetes a leveler of efficacy of DES types? *Catheter Cardiovasc Interv* 2010;75:335-7
22. Sibbing D; von Beckerath N; Morath T; Stegherr J; Mehilli J; Sarafoff N; Braun S; Schulz S; Schomig A; Kastrati A. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. *Eur Heart J* 2010;31:1205-11
23. Sibbing D; Stegherr J; Braun S; Mehilli J; Schulz S; Seyfarth M; Kastrati A; von Beckerath N; Schomig A. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. *J Am Coll Cardiol* 2010;55:558-65
24. Schulz S; Mehilli J; Ndrepepa G; Neumann FJ; Birkmeier KA; Kufner S; Richardt G; Berger PB; Schomig A; Kastrati A; Intracoronary S; Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 3 Trial I. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. *Eur Heart J* 2010;31:582-7
25. Ndrepepa G; Tiroch K; Keta D; Fusaro M; Seyfarth M; Pache J; Mehilli J; Schomig A; Kastrati A. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. *Circ Cardiovasc Interv* 2010;3:27-33
26. Ndrepepa G; Schulz S; Keta D; Mehilli J; Birkmeier A; Massberg S; Laugwitz KL; Neumann FJ; Seyfarth M; Berger PB; Schomig A; Kastrati A. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. *Am J Cardiol* 2010;105:163-7
27. Ndrepepa G; Keta D; Byrne RA; Schulz S; Mehilli J; Seyfarth M; Schomig A; Kastrati A. Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. *Heart Vessels* 2010;25:27-34
28. Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. *Catheter Cardiovasc Interv* 2010;75:895-902
29. Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schomig A; von Beckerath N; Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation* 2010;121:512-8
30. Stein A; Zohnhofer D; Pogatsa-Murray G; von Wedel J; Steppich BA; Schomig A; Kastrati A; Ott I. Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. *Thromb Haemost* 2010;103:638-43
31. Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schomig A; Kastrati A; von Beckerath N. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. *Thromb Haemost* 2010;103:151-9
32. Wessely R; Koppa T; Bradaric C; Vorpahl M; Braun S; Schulz S; Mehilli J; Schomig A; Kastrati A; Contrast M; Nephrotoxicity Following Coronary Revascularization by Angioplasty Trial I. Choice of

contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv* 2009;2:430-7

33. Echtler K; Stark K; Lorenz M; Kerstan S; Walch A; Jennen L; Rudelius M; Seidl S; Kremmer E; Emambokus NR; von Bruehl ML; Frampton J; Isermann B; Genzel-Boroviczeny O; Schreiber C; Mehilli J; Kastrati A; Schwaiger M; Shivdasani RA; Massberg S. Platelets contribute to postnatal occlusion of the ductus arteriosus. *Nat Med* 2010;16:75-82
34. Sibbing D; Schulz S; Braun S; Morath T; Stegherr J; Mehilli J; Schomig A; von Beckerath N; Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. *J Thromb Haemost* 2010;8:250-6

2009

1. Hoppmann P; Erl A; Turk S; Tiroch K; Mehilli J; Schomig A; Kastrati A; Koch W. No association of chromosome 9p21.3 variation with clinical and angiographic outcomes after placement of drug-eluting stents. *JACC Cardiovasc Interv* 2009;2:1149-55
2. Kufner S; Hausleiter J; Ndrepepa G; Schulz S; Bruskina O; Byrne RA; Fusaro M; Kastrati A; Schomig A; Mehilli J; Investigators OT. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. *JACC Cardiovasc Interv* 2009;2:1142-8
3. Kastrati A; Ndrepepa G. Cangrelor - a champion lost in translation? *N Engl J Med* 2009;361:2382-4
4. Braun S; von Beckerath N; Ellert J; Kastrati A; Schomig A; Vogt W; Sibbing D. Assessment of platelet function in whole blood by multiple electrode aggregometry: transport of samples using a pneumatic tube system. *Am J Clin Pathol* 2009;132:802-3; author reply 803-4
5. Byrne RA; Joner M; Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. *Minerva Cardioangiolog* 2009;57:567-84
6. von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schomig A; Kastrati A. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. *Blood Coagul Fibrinolysis* 2010;21:46-52
7. Ndrepepa G; Keta D; Schulz S; Byrne RA; Mehilli J; Pache J; Seyfarth M; Schomig A; Kastrati A. Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. *Clin Res Cardiol* 2010;99:13-9
8. Koch W; de Waha A; Hoppmann P; Schomig A; Kastrati A. Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and a meta-analysis. *Atherosclerosis* 2010;208:171-6
9. Van de Werf F; Bax J; Betriu A; Blomstrom-Lundqvist C; Crea F; Falk V; Filippatos G; Fox K; Huber K; Kastrati A; Rosengren A; Steg PG; Tubaro M; Verheugt F; Weidinger F; Weis M; Task Force per il Trattamento dell'Infarto Miocardico Acuto c; Sopraslivellamento del Tratto STdSEdC; Vahanian A; Camm J; De Caterina R; Dean V; Dickstein K; Filippatos G; Funck-Brentano C; Hellemans I; Kristensen SD; McGregor K; Sechtem U; Silber S; Tendera M; Widimsky P; Zamorano JL; Silber S; Aguirre FV; Al-Attar N; Alegria E; Andreotti F; Benzer W; Breithardt O; Danchin N; Di Mario C; Dudek D; Gulba D; Halvorsen S; Kaufmann P; Kornowski R; Lip GY; Rutten F; Societa Europea di C. [Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. *G Ital Cardiol (Rome)* 2009;10:450-89
10. Sibbing D; Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction? *Lancet* 2009;374:952-4

11. Byrne RA; Kastrati A; Kufner S; Massberg S; Birkmeier KA; Laugwitz KL; Schulz S; Pache J; Fusaro M; Seyfarth M; Schomig A; Mehilli J; Intracoronary S; Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents I. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. *Eur Heart J* 2009;30:2441-9
12. Roos M; Ndrepepa G; Baumann M; Pan CR; Heemann U; Lutz J; Keta D; Schulz S; Byrne RA; Mehilli J; Schomig A; Kastrati A. Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. *Clin Chim Acta* 2009;409:46-51
13. Koch W; Hoppmann P; Schomig A; Kastrati A. Variations of specific non-candidate genes and risk of myocardial infarction: a replication study. *Int J Cardiol* 2011;147:38-41
14. Byrne RA; Sarafoff N; Kastrati A; Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. *Drug Saf* 2009;32:749-70
15. Schulz S; Schuster T; Mehilli J; Byrne RA; Ellert J; Massberg S; Goedel J; Bruskina O; Ulm K; Schomig A; Kastrati A. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. *Eur Heart J* 2009;30:2714-21
16. Seyfarth M; Kastrati A; Mann JF; Ndrepepa G; Byrne RA; Schulz S; Mehilli J; Schomig A. Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. *Am J Kidney Dis* 2009;54:830-9
17. Bauer A; Mehilli J; Barthel P; Muller A; Kastrati A; Ulm K; Schomig A; Malik M; Schmidt G. Impact of myocardial salvage assessed by (99m)Tc-sestamibi scintigraphy on cardiac autonomic function in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. *JACC Cardiovasc Imaging* 2009;2:449-57
18. Hadamitzky M; Freissmuth B; Meyer T; Hein F; Kastrati A; Martinoff S; Schomig A; Hausleiter J. Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. *JACC Cardiovasc Imaging* 2009;2:404-11
19. Ndrepepa G; Schomig A; Kastrati A. The only better alternative to rescue percutaneous coronary intervention is primary percutaneous coronary intervention. *J Am Coll Cardiol* 2009;54:127-9
20. Steppich BA; Braun SL; Stein A; Demetz G; Groha P; Schomig A; von Beckerath N; Kastrati A; Ott I. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. *Thromb J* 2009;7:11
21. Byrne RA; Eberle S; Kastrati A; Dibra A; Ndrepepa G; Iijima R; Mehilli J; Schomig A. Distribution of angiographic measures of restenosis after drug-eluting stent implantation. *Heart* 2009;95:1572-8
22. Byrne RA; Iijima R; Mehilli J; Piniack S; Bruskina O; Schomig A; Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. *JACC Cardiovasc Interv* 2009;2:291-9
23. John MC; Wessely R; Kastrati A; Schomig A; Joner M; Uchihashi M; Crimins J; Lajoie S; Kolodgie FD; Gold HK; Virmani R; Finn AV. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. *JACC Cardiovasc Interv* 2008;1:535-44
24. Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schomig A; Stenting L-MI; Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study I. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2009;53:1760-8
25. Iijima R; Byrne RA; Dibra A; Ndrepepa G; Spaulding C; Laarman GJ; Menichelli M; Valgimigli M; Di Lorenzo E; Kaiser C; Tierala I; Mehilli J; Suttrop MJ; Violini R; Schomig A; Kastrati A. Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial

- infarction: a pooled analysis of individual patient data from seven randomized trials. *Rev Esp Cardiol* 2009;62:354-64
26. Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schomig A; Kastrati A; von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. *Thromb Haemost* 2009;101:714-9
 27. Mehilli J; Kastrati A; Schulz S; Frungel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schomig A; Bavarian Reperfusion Alternatives Evaluation-3 Study I. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. *Circulation* 2009;119:1933-40
 28. Byrne RA; Schulz S; Mehilli J; Iijima R; Massberg S; Neumann FJ; ten Berg JM; Schomig A; Kastrati A; Intracoronary S; Antithrombotic Regimen S; Investigators EFoSM DATAD-ES. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. *Am Heart J* 2009;157:620-4 e2
 29. Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevaliers B; DiMario C; Fajadeto J; Gitt A; Guagliumi G; Hillege HL; James S; Juni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Berenger M; Boam A; Calle JP; Campo G; Carlier S; de Schepper J; Di Bisceglie G; Dobbels H; Farb A; Ghislain JC; Hellbardt S; ten Hoedt R; Isaia C; de Jong P; Lekehal M; LeNarz L; Mhullain FN; Nagai H; Patteet A; Paunovic D; Potgieter A; Purdy I; Raveau-Landon C; Ternstrom S; Van Wuytswinkel J; Waliszewski M; European Society of C. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. *EuroIntervention* 2009;4:427-36
 30. Task Force on the management of STseami; Van de Werf F; Bax J; Betriu A; Blomstrom-Lundqvist C; Crea F; Falk V; Filippatos G; Fox K; Huber K; Kastrati A; Rosengren A; Steg PG; Tubaro M; Verheugt F; Weidinger F; Weis M. ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. *Rev Esp Cardiol* 2009;62:293, e1-47
 31. Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schomig A; Kastrati A; von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. *J Am Coll Cardiol* 2009;53:849-56
 32. Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schomig A; Kastrati A. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. *Eur Heart J* 2009;30:923-31
 33. Ndrepepa G; Mehilli J; Schulz S; Iijima R; Keta D; Byrne RA; Pache J; Seyfarth M; Schomig A; Kastrati A. Patterns of presentation and outcomes of patients with acute coronary syndromes. *Cardiology* 2009;113:198-206
 34. Sibbing D; Stegherr J; Latz W; Koch W; Mehilli J; Dorrlor K; Morath T; Schomig A; Kastrati A; von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. *Eur Heart J* 2009;30:916-22
 35. Busch G; Steppich B; Sibbing D; Braun SL; Stein A; Groha P; Schomig A; Kastrati A; von Beckerath N; Ott I. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. *Thromb Haemost* 2009;101:340-4
 36. Hausleiter J; Meyer T; Hermann F; Hadamitzky M; Krebs M; Gerber TC; McCollough C; Martinoff S; Kastrati A; Schomig A; Achenbach S. Estimated radiation dose associated with cardiac CT angiography. *JAMA* 2009;301:500-7

37. Ndrepepa G; Kastrati A; Mehilli J; Antoniucci D; Schomig A. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. *JAMA* 2009;301:487-8
38. Finn AV; Oh JS; Hendricks M; Daher M; Cagliero E; Byrne RM; Nadelson J; Crimins J; Kastrati A; Schomig A; Bruskin O; Palacios I; John MC; Gold HK. Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. *Am Heart J* 2009;157:383 e1-8
39. Iijima R; Ndrepepa G; Mehilli J; Byrne RA; Schulz S; Neumann FJ; Richardt G; Berger PB; Schomig A; Kastrati A. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. *Eur Heart J* 2009;30:290-6
40. Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevalier B; Dimario C; Fajadet J; Gitt A; Guagliumi G; Hillege HL; James S; Juni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Baczynska A; Bagust A; Berenger M; Bos G; Boam A; Bowen JM; Braunwald E; Calle JP; Camenzind E; Campo G; Carlier S; Chevalier B; Daemen J; de Schepper J; Di Bisceglie G; Dimario C; Dobbels H; Fajadet J; Farb A; Ghislain JC; Gitt A; Guagliumi G; Hellbardt S; Hillege HL; Ten Hoedt R; Isaia C; James S; de Jong P; Juni P; Kastrati A; Klasen E; Kloth S; Kristensen SD; Krucoff M; Legrand V; Lekehal M; Lenarz L; Ni Mhullain F; Nagai H; Patteet A; Paunovic D; Pfisterer M; Potgieter A; Purdy I; Raveau-Landon C; Rothman M; Serruys PW; Silber S; Simoons ML; Steg PG; Tariah I; Ternstrom S; Van Wuytswinkel J; Waliszewski M; Wallentin L; Wijns W; Windecker SW. ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. *Eur Heart J* 2009;30:152-61
41. Koch W; Hoppmann P; Mueller JC; Schomig A; Kastrati A. Lack of support for association between common variation in TNFSF4 and myocardial infarction in a German population. *Nat Genet* 2008;40:1386-7; author reply 1387-8
42. Byrne RA; Kastrati A. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. *Catheter Cardiovasc Interv* 2008;72:944-9
43. Seyfarth M; Sibbing D; Bauer I; Frohlich G; Bott-Flugel L; Byrne R; Dirschinger J; Kastrati A; Schomig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. *J Am Coll Cardiol* 2008;52:1584-8
44. Van de Werf F; Bax J; Betriu A; Blomstrom-Lundqvist C; Crea F; Falk V; Filippatos G; Fox K; Huber K; Kastrati A; Rosengren A; Steg PG; Tubaro M; Verheugt F; Weidinger F; Weis M; Guidelines ESCCfP. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 2008;29:2909-45
45. Adriaenssens T; Byrne RA; Dibra A; Iijima R; Mehilli J; Bruskin O; Schomig A; Kastrati A. Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. *Eur Heart J* 2008;29:2868-76
46. Byrne R; Iijima R; Mehilli J; Pache J; Schulz S; Schomig A; Kastrati A. [Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes]. *Rev Esp Cardiol* 2008;61:1134-9
47. Steigerwald K; Merl S; Kastrati A; Wiecek A; Vorpahl M; Mannhold R; Vogeser M; Hausleiter J; Joner M; Schomig A; Wessely R. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. *Biomaterials* 2009;30:632-7
48. Ndrepepa G; Braun S; Iijima R; Keta D; Byrne RA; Schulz S; Mehilli J; Schomig A; Kastrati A. Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute

coronary syndromes treated with percutaneous coronary intervention. *Clin Sci (Lond)* 2009;116:651-8

49. Mylotte D; Byrne RA; Iijima R; Kastrati A. Multivessel percutaneous coronary intervention: a review of the literature and fallacies in its interpretation. *Minerva Cardioangiol* 2008;56:493-510
50. Iijima R; Byrne RA; Ndrepepa G; Braun S; Mehilli J; Berger PB; Schomig A; Kastrati A. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. *Heart* 2009;95:107-12
51. Schomig A; Mehilli J; de Waha A; Seyfarth M; Pache J; Kastrati A. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. *J Am Coll Cardiol* 2008;52:894-904
52. Tiroch K; Koch W; Mehilli J; Bottiger C; Schomig A; Kastrati A. P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. *Cardiology* 2009;112:263-9

2008

1. Stettler C; Allemann S; Wandel S; Kastrati A; Morice MC; Schomig A; Pfisterer ME; Stone GW; Leon MB; de Lezo JS; Goy JJ; Park SJ; Sabate M; Suttorp MJ; Kelbaek H; Spaulding C; Menichelli M; Vermeersch P; Dirksen MT; Cervinka P; De Carlo M; Erglis A; Chechi T; Ortolani P; Schalij MJ; Diem P; Meier B; Windecker S; Juni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. *BMJ* 2008;337:a1331
2. Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Buttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schomig A; Investigators I-RT. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. *N Engl J Med* 2008;359:688-96
3. Ndrepepa G; Mehilli J; Schulz S; Iijima R; Keta D; Byrne RA; Pache J; Seyfarth M; Schomig A; Kastrati A. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. *J Am Coll Cardiol* 2008;52:512-7
4. Sarafoff N; Ndrepepa G; Mehilli J; Dorrlor K; Schulz S; Iijima R; Byrne R; Schomig A; Kastrati A. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. *J Intern Med* 2008;264:472-80
5. Friedewald VE, Jr.; Kastrati A; Roberts WC; Vetrovec GW; Windecker S. The editor's roundtable: bare-metal stents versus drug-eluting stents-indications and complications. *Am J Cardiol* 2008;102:32-9
6. Mehilli J; Byrne RA; Wieczorek A; Iijima R; Schulz S; Bruskina O; Pache J; Wessely R; Schomig A; Kastrati A; Intracoronary S; Angiographic Restenosis Investigators--Test Efficacy of Rapamycin-eluting Stents with Different Polymer Coating S. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. *Eur Heart J* 2008;29:1975-82
7. Vorpahl M; Laugwitz KL; Zrenner B; Kastrati A; Schomig A. Unusual use of a standard percutaneous transluminal coronary angioplasty balloon catheter to the rescue. *Eur Heart J* 2008;29:2732
8. Sibbing D; Busch G; Braun S; Jawansky S; Schomig A; Kastrati A; Ott I; von Beckerath N. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. *Eur Heart J* 2008;29:1504-9

9. Sibbing D; Taubert D; Schomig A; Kastrati A; Von Beckerath N. Pharmacokinetics of clopidogrel in patients with stent thrombosis. *J Thromb Haemost* 2008;6:1230-2
10. Iijima R; Ndrepepa G; Mehilli J; Dirschinger J; Pache J; Seyfarth M; Schomig A; Kastrati A. Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. *Am J Cardiol* 2008;101:1226-31
11. Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schomig A. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. *Cardiology* 2008;111:247-53
12. Zohlnhofer D; Dibra A; Koppa T; de Waha A; Ripa RS; Kastrup J; Valgimigli M; Schomig A; Kastrati A. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. *J Am Coll Cardiol* 2008;51:1429-37
13. Kastrati A. Drug for a while, polymer for life: Is it a good solution? *Catheter Cardiovasc Interv* 2008;71:340-1
14. Ndrepepa G; Berger PB; Mehilli J; Seyfarth M; Neumann FJ; Schomig A; Kastrati A. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. *J Am Coll Cardiol* 2008;51:690-7
15. Ndrepepa G; Braun S; Mehilli J; von Beckerath N; Schomig A; Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. *Eur J Clin Invest* 2008;38:90-6
16. Sibbing D; Braun S; Jawansky S; Vogt W; Mehilli J; Schomig A; Kastrati A; von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. *Thromb Haemost* 2008;99:121-6
17. Stefanescu A; Braun S; Ndrepepa G; Koppa T; Pavaci H; Mehilli J; Schomig A; Kastrati A. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. *Am Heart J* 2008;155:356-60
18. Kastrati A; Schomig A. Are sirolimus-eluting stents superior to paclitaxel-eluting stents in patients with small-vessel disease? *Nat Clin Pract Cardiovasc Med* 2008;5:188-9
19. Koch W; Hoppmann P; Biele J; Mueller JC; Schomig A; Kastrati A. Fibrinogen genes and myocardial infarction: a haplotype analysis. *Arterioscler Thromb Vasc Biol* 2008;28:758-63
20. Koch W; Hoppmann P; de Waha A; Schomig A; Kastrati A. Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. *Hum Mol Genet* 2008;17:1120-6
21. Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Berger PB; Schomig A. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. *Eur Heart J* 2008;29:455-61
22. Sotgia B; Sciagra R; Parodi G; Kastrati A; Antonucci D; Schomig A; Pupi A. Estimate of myocardial salvage in late presentation acute myocardial infarction by comparing functional and perfusion abnormalities in predischARGE gated SPECT. *Eur J Nucl Med Mol Imaging* 2008;35:906-11
23. Iijima R; Ndrepepa G; Mehilli J; Neumann FJ; Schulz S; ten Berg J; Bruskina O; Dotzer F; Dirschinger J; Berger PB; Schomig A; Kastrati A. Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. *Clin Res Cardiol* 2008;97:160-8
24. Nuhrenberg TG; Langwieser N; Schwarz JB; Hou Y; Frank P; Sorge F; Matschurat S; Seidl S; Kastrati A; Schomig A; Clauss MA; Zohlnhofer D. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. *Cardiovasc Res* 2008;77:580-9

25. Louvard Y; Thomas M; Dzavik V; Hildick-Smith D; Galassi AR; Pan M; Burzotta F; Zelizko M; Dudek D; Ludman P; Sheiban I; Lassen JF; Darremont O; Kastrati A; Ludwig J; Iakovou I; Brunel P; Lansky A; Meerkin D; Legrand V; Medina A; Lefevre T. Classification of coronary artery bifurcation lesions and treatments: time for a consensus! *Catheter Cardiovasc Interv* 2008;71:175-83
26. Roos M; Lutz J; Salmhofer H; Lupp A; Knauss A; Braun S; Martinof S; Schomig A; Heemann U; Kastrati A; Hausleiter J. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. *Clin Endocrinol (Oxf)* 2008;68:660-5
27. Iijima R; Ndrepepa G; Mehilli J; Bruskin O; Schulz S; Schomig A; Kastrati A. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. *Thromb Haemost* 2007;98:852-7
28. Wessely R; Kastrati A; Mehilli J; Dibra A; Pache J; Schomig A. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. *Eur Heart J* 2007;28:2720-5
29. Schomig A; Dibra A; Windecker S; Mehilli J; Suarez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Juni P; Pfisterer ME; Meier B; Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. *J Am Coll Cardiol* 2007;50:1373-80
30. Kastrati A; Dibra A; Spaulding C; Laarman GJ; Menichelli M; Valgimigli M; Di Lorenzo E; Kaiser C; Tierala I; Mehilli J; Seyfarth M; Varenne O; Dirksen MT; Percoco G; Varricchio A; Pittl U; Syvanne M; Suttorp MJ; Violini R; Schomig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. *Eur Heart J* 2007;28:2706-13
31. Iijima R; Ndrepepa G; Mehilli J; Markwardt C; Bruskin O; Pache J; Ibrahim M; Schomig A; Kastrati A. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. *Am Heart J* 2007;154:688-93
32. Kalyanasundaram A; Berger P; Kastrati A. Effects of glycoprotein IIb/IIIa blockers. *Heart* 2007;93:1293; author reply 1293
33. Ndrepepa G; Braun S; Mehilli J; Schomig A; Kastrati A. Accuracy of N-terminal probrain natriuretic peptide to predict mortality or detect acute ischemia in patients with coronary artery disease. *Cardiology* 2008;109:249-57
34. Stettler C; Wandel S; Allemann S; Kastrati A; Morice MC; Schomig A; Pfisterer ME; Stone GW; Leon MB; de Lezo JS; Goy JJ; Park SJ; Sabate M; Suttorp MJ; Kelbaek H; Spaulding C; Menichelli M; Vermeersch P; Dirksen MT; Cervinka P; Petronio AS; Nordmann AJ; Diem P; Meier B; Zwahlen M; Reichenbach S; Trelle S; Windecker S; Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet* 2007;370:937-48
35. Schomig K; Ndrepepa G; Mehilli J; Pache J; Kastrati A; Schomig A. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. *Catheter Cardiovasc Interv* 2007;70:359-65
36. Adriaenssens T; Kastrati A; Schomig A. Successful stenting of bilateral multiple renal arteries in a patient with renovascular hypertension. *J Invasive Cardiol* 2007;19:E235-7
37. Ndrepepa G; Braun S; Schomig A; Kastrati A. Accuracy of N-terminal pro-brain natriuretic peptide to predict mortality in various subsets of patients with coronary artery disease. *Am J Cardiol* 2007;100:575-8
38. Ndrepepa G; Braun S; Kastrati A; Schomig A. Area under ROC curve, sensitivity, specificity of N-terminal probrain natriuretic peptide in predicting mortality in various subsets of patients with ischemic heart disease. *Clin Res Cardiol* 2007;96:763-5

39. Sibbing D; von Beckerath O; Schomig A; Kastrati A; von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. *Am J Cardiol* 2007;100:203-5
40. Ndrepepa G; Mehilli J; Martinoff S; Schwaiger M; Schomig A; Kastrati A. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. *J Am Coll Cardiol* 2007;50:149-56
41. Kastrati A; Schomig A. Drug-eluting stents is their future as bright as their past? *J Am Coll Cardiol* 2007;50:146-8
42. Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schomig A. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. *Am Heart J* 2007;154:158 e1-7
43. Steinhubl SR; Kastrati A; Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. *Am Heart J* 2007;154:3-11
44. Wessely R; Blaich B; Belaiba RS; Merl S; Gorlach A; Kastrati A; Schomig A. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. *Thromb Haemost* 2007;97:1003-12
45. De Luca G; Suryapranata H; Stone GW; Antoniucci D; Biondi-Zoccai G; Kastrati A; Chiariello M; Marino P. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. *Int J Cardiol* 2008;126:37-44

2007

1. Hausleiter J; Meyer T; Hadamitzky M; Zankl M; Gerein P; Dorrlor K; Kastrati A; Martinoff S; Schomig A. Non-invasive coronary computed tomographic angiography for patients with suspected coronary artery disease: the Coronary Angiography by Computed Tomography with the Use of a Submillimeter resolution (CACTUS) trial. *Eur Heart J* 2007;28:3034-41
2. Koch W; Hoppmann P; Michou E; Jung V; Pfeufer A; Mueller JC; Gieger C; Wichmann HE; Meitinger T; Schomig A; Kastrati A. Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans. *Hum Mol Genet* 2007;16:1821-7
3. Sibbing D; von Beckerath O; Schomig A; Kastrati A; von Beckerath N. Platelet function in clopidogrel-treated patients with acute coronary syndrome. *Blood Coagul Fibrinolysis* 2007;18:335-9
4. Ndrepepa G; Schomig A; Kastrati A. Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: looking for the reasons. *JAMA* 2007;297:1711-3
5. Koch W; Hoppmann P; Schomig A; Kastrati A. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. *Int J Cardiol* 2008;125:116-7
6. Tiroch K; Koch W; von Beckerath N; Kastrati A; Schomig A. Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. *Eur Heart J* 2007;28:968-73
7. Adriaenssens T; Mehilli J; Wessely R; Ndrepepa G; Seyfarth M; Wieczorek A; Blaich B; Iijima R; Pache J; Kastrati A; Schomig A. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. *J Am Coll Cardiol* 2007;49:1265-71

8. Boettiger C; Koch W; Mehilli J; Schoemig A; Kastrati A. Glycoprotein VI polymorphisms and outcome after percutaneous coronary interventions. *Thromb Haemost* 2007;97:673-4
9. Meyer TS; Martinoff S; Hadamitzky M; Will A; Kastrati A; Schomig A; Hausleiter J. Improved noninvasive assessment of coronary artery bypass grafts with 64-slice computed tomographic angiography in an unselected patient population. *J Am Coll Cardiol* 2007;49:946-50
10. Koch W; Hoppmann P; Mueller JC; Schomig A; Kastrati A. No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. *Genet Med* 2007;9:123-9
11. Kastrati A; Mehilli J; Pache J; Kaiser C; Valgimigli M; Kelbaek H; Menichelli M; Sabate M; Suttorp MJ; Baumgart D; Seyfarth M; Pfisterer ME; Schomig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. *N Engl J Med* 2007;356:1030-9
12. Dibra A; Kastrati A; Alfonso F; Seyfarth M; Perez-Vizcayno MJ; Mehilli J; Schomig A. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. *J Am Coll Cardiol* 2007;49:616-23
13. von Beckerath N; Kastrati A; Wiecek A; Pogatsa-Murray G; Sibbing D; Graf I; Schomig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. *Eur Heart J* 2007;28:1814-9
14. Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. *Eur Heart J* 2007;28:443-9
15. Zohnhofer D; Kastrati A; Schomig A. Stem cell mobilization by granulocyte-colony-stimulating factor in acute myocardial infarction: lessons from the REVIVAL-2 trial. *Nat Clin Pract Cardiovasc Med* 2007;4 Suppl 1:S106-9
16. Parodi G; Ndrepepa G; Kastrati A; Conti A; Mehilli J; Sciagra R; Schwaiger M; Antoniucci D; Schomig A; Beyond 12 hours Reperfusion Alternative Evaluation Trial I. Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. *Am Heart J* 2006;152:1133-9
17. Kastrati A; Elezi S; Schomig A. [A friend in need is a friend indeed: the case of drug-eluting stents, diabetes and small vessel size]. *Rev Esp Cardiol* 2006;59:991-3
18. Taubert D; von Beckerath N; Grimberg G; Lazar A; Jung N; Goeser T; Kastrati A; Schomig A; Schomig E. Impact of P-glycoprotein on clopidogrel absorption. *Clin Pharmacol Ther* 2006;80:486-501
19. Ndrepepa G; Braun S; Mehilli J; Niemoller K; Schomig A; Kastrati A. A prospective cohort study of prognostic power of N-terminal pro-brain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. *Clin Res Cardiol* 2007;96:30-7

2006

1. Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskin O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Ulm K; Berger PB; Schomig A. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. *Circulation* 2006;114:2040-6
2. Lazar A; Zimmermann T; Koch W; Grundemann D; Schomig A; Kastrati A; Schomig E. Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension. *Clin Exp Hypertens* 2006;28:645-53

3. Pache J; Dibra A; Schaut C; Schuhlen H; Dirschinger J; Mehilli J; Kastrati A; Schomig A. Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stents. *Catheter Cardiovasc Interv* 2006;68:690-5
4. Ndrepepa G; Kastrati A; Braun S; Koch W; Kolling K; Mehilli J; Schomig A. Circulating homocysteine levels in patients with type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis* 2008;18:66-73
5. Iijima R; Mehilli J; Schomig A; Kastrati A. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents. *Minerva Cardioangiol* 2006;54:539-55
6. Elezi S; Dibra A; Mehilli J; Pache J; Wessely R; Schomig A; Kastrati A. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. *J Am Coll Cardiol* 2006;48:1304-9
7. Koch W; Hoppmann P; Pfeufer A; Schomig A; Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. *Eur Heart J* 2006;27:2524-9
8. Schulz C; Schomig A; Kastrati A. Acute coronary artery stent thrombosis following rapid renewal of functional platelets: implications for intensified antiplatelet therapy. *Thromb Haemost* 2006;96:384-6
9. Sibbing D; von Beckerath O; Schomig A; Kastrati A; von Beckerath N. Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. *J Thromb Haemost* 2006;4:2566-8
10. Hausleiter J; Kastrati A. Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation? *Nat Clin Pract Cardiovasc Med* 2006;3:476-7
11. Schomig A; Ndrepepa G; Kastrati A. Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. *Eur Heart J* 2006;27:1900-7
12. Hausleiter J; Meyer T; Hadamitzky M; Kastrati A; Martinoff S; Schomig A. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. *J Am Coll Cardiol* 2006;48:312-8
13. Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schomig A; Kastrati A. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease. *J Am Coll Cardiol* 2006;48:262-7
14. Ndrepepa G; Kastrati A; Braun S; Koch W; Kolling K; Mehilli J; Schomig A. A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. *Clin Chim Acta* 2006;373:70-6
15. Schuhlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schomig A. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. *Am Heart J* 2006;151:1248-54
16. Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schomig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. *Circulation* 2006;113:2293-300
17. von Beckerath N; Pogatsa-Murray G; Wieczorek A; Sibbing D; Schomig A; Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. *Thromb Haemost* 2006;95:910-1
18. Sibbing D; von Beckerath O; Schomig A; Kastrati A; von Beckerath N. P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. *J Thromb Haemost* 2006;4:912-4

19. Ndrepepa G; Braun S; Mehilli J; von Beckerath N; Nekolla S; Vogt W; Schwaiger M; Schomig A; Kastrati A. N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. *Am J Cardiol* 2006;97:1151-6
20. Ndrepepa G; Kastrati A; Braun S; Mehilli J; Niemoller K; von Beckerath N; von Beckerath O; Vogt W; Schomig A. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. *Am J Med* 2006;119:355 e1-8
21. Koch W; Hoppmann P; Mueller JC; Schomig A; Kastrati A. Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. *Arterioscler Thromb Vasc Biol* 2006;26:1114-9
22. Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schuhlen H; Dirschinger J; Berger PB; Schomig A; Intracoronary S; Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 Trial I. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. *JAMA* 2006;295:1531-8
23. Hausleiter J; Meyer T; Hadamitzky M; Huber E; Zankl M; Martinoff S; Kastrati A; Schomig A. Radiation dose estimates from cardiac multislice computed tomography in daily practice: impact of different scanning protocols on effective dose estimates. *Circulation* 2006;113:1305-10
24. Zohlnhofer D; Ott I; Mehilli J; Schomig K; Michalk F; Ibrahim T; Meisetschlager G; von Wedel J; Bollwein H; Seyfarth M; Dirschinger J; Schmitt C; Schwaiger M; Kastrati A; Schomig A; Investigators R-. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. *JAMA* 2006;295:1003-10
25. Wessely R; Schomig A; Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. *J Am Coll Cardiol* 2006;47:708-14
26. Elezi S; Dibra A; Schomig A; Kastrati A. Current drug-eluting stents in complex patients and lesions. *Minerva Cardioangiol* 2006;54:5-22
27. Mehilli J; Dibra A; Kastrati A; Pache J; Dirschinger J; Schomig A; Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries Study I. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. *Eur Heart J* 2006;27:260-6
28. Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schomig A; Intracoronary S; Angiographic Restenosis--Test Equivalence Between 2 Drug-Eluting Stents Trial I. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. *Circulation* 2006;113:273-9

2005

1. Zohlnhofer D; Hausleiter J; Kastrati A; Mehilli J; Goos C; Schuhlen H; Pache J; Pogatsa-Murray G; Heemann U; Dirschinger J; Schomig A. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. *J Am Coll Cardiol* 2005;46:1999-2003
2. Ndrepepa G; Braun S; Dibra A; Mehilli J; Vogt W; Schomig A; Kastrati A. Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. *Nutr Metab Cardiovasc Dis* 2005;15:418-25
3. Ndrepepa G; Kastrati A; Schwaiger M; Mehilli J; Markwardt C; Dibra A; Dirschinger J; Schomig A. Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. *J Nucl Med* 2005;46:1782-8

4. Schomig A; Kastrati A; Wessely R. Prevention of restenosis by systemic drug therapy: back to the future? *Circulation* 2005;112:2759-61
5. von Beckerath N; Taubert D; Pogatsa-Murray G; Schomig E; Kastrati A; Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. *Circulation* 2005;112:2946-50
6. Dibra A; Ndrepepa G; Mehilli J; Pineck S; Mayer S; Bollwein H; Hausleiter J; Pache J; Schomig A; Kastrati A. Prognostic value of impaired fasting glucose for outcomes of patients with stable angina pectoris treated with percutaneous coronary interventions. *Am J Cardiol* 2005;96:1113-5
7. Koch W; Hoppmann P; Pfeufer A; Mueller JC; Schomig A; Kastrati A. No replication of association between estrogen receptor alpha gene polymorphisms and susceptibility to myocardial infarction in a large sample of patients of European descent. *Circulation* 2005;112:2138-42
8. Ndrepepa G; Braun S; Niemoller K; Mehilli J; von Beckerath N; von Beckerath O; Vogt W; Schomig A; Kastrati A. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. *Circulation* 2005;112:2102-7
9. Sibbing D; von Beckerath O; von Beckerath N; Koch W; Mehilli J; Schwaiger M; Schomig A; Kastrati A. Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. *Blood Coagul Fibrinolysis* 2005;16:511-5
10. Braun S; Ndrepepa G; von Beckerath N; Mehilli J; Gorchakova O; Vogt W; Schomig A; Kastrati A. Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. *Am Heart J* 2005;150:550-6
11. Tiroch K; von Beckerath N; Koch W; Lengdabler J; Joost A; Schomig A; Kastrati A. Interferon-gamma and interferon-gamma receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting. *Atherosclerosis* 2005;182:145-51
12. Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schomig A; Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. *Cardiovasc Res* 2005;68:483-92
13. Wessely R; Kastrati A; Schomig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. *Ann Intern Med* 2005;143:392-4
14. Kastrati A; Dibra A; Eberle S; Mehilli J; Suarez de Lezo J; Goy JJ; Ulm K; Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. *JAMA* 2005;294:819-25
15. Dibra A; Kastrati A; Mehilli J; Pache J; Schuhlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schomig A; Investigators I-DS. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. *N Engl J Med* 2005;353:663-70
16. Dibra A; Mehilli J; Braun S; Hadamitzky M; Baum H; Dirschinger J; Schuhlen H; Schomig A; Kastrati A. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. *Am Heart J* 2005;150:344-50
17. Koch W; Latz W; Eichinger M; Ganser C; Schomig A; Kastrati A. Genotyping of the angiotensin I-converting enzyme gene insertion/deletion polymorphism by the TaqMan method. *Clin Chem* 2005;51:1547-9
18. Ndrepepa G; Braun S; von Beckerath N; Mehilli J; Gorchakova O; Vogt W; Schomig A; Kastrati A. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. *Clin Chim Acta* 2005;360:178-86
19. Hausleiter J; Kastrati A; Wessely R; Dibra A; Mehilli J; Schratzenstaller T; Graf I; Renke-Gluszko M; Behnisch B; Dirschinger J; Wintermantel E; Schomig A; investigators of the individualizable durg-

- eluting Stent System to Abrogate Restenosis P. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. *Eur Heart J* 2005;26:1475-81
20. Schomig A; Mehilli J; Antoniucci D; Ndrepepa G; Markwardt C; Di Pede F; Nekolla SG; Schlotterbeck K; Schuhlen H; Pache J; Seyfarth M; Martinoff S; Benzer W; Schmitt C; Dirschinger J; Schwaiger M; Kastrati A; Beyond 12 hours Reperfusion Alternative Evaluation Trial I. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. *JAMA* 2005;293:2865-72
 21. Dibra A; Kastrati A; Mehilli J; Pache J; von Oepen R; Dirschinger J; Schomig A. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial. *Catheter Cardiovasc Interv* 2005;65:374-80
 22. Windecker S; Simon R; Lins M; Klauss V; Eberli FR; Roffi M; Pedrazzini G; Moccetti T; Wenaweser P; Togni M; Tuller D; Zbinden R; Seiler C; Mehilli J; Kastrati A; Meier B; Hess OM. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. *Circulation* 2005;111:2617-22
 23. Dibra A; Ndrepepa G; Mehilli J; Dirschinger J; Pache J; Schuhlen H; Schomig A; Kastrati A. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. *Am J Cardiol* 2005;95:1238-40
 24. Koch W; Hoppmann P; Michou E; Jung V; Pfeufer A; Muller J; Meitinger T; Schomig A; Kastrati A. TaqMan assays for genotyping of single nucleotide polymorphisms present at a disease susceptibility locus on chromosome 6. *Clin Chem Lab Med* 2005;43:167-72
 25. von Beckerath N; Taubert D; Pogatsa-Murray G; Wieczorek A; Schomig E; Schomig A; Kastrati A. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. *Thromb Haemost* 2005;93:789-91
 26. Unverdorben M; Degenhardt R; Sick P; Kastrati A; Desmet W; Colombo A; Garcia E; Klein W; Wagner E; Kohler H; Scholz M; Berthold HK; Vallbracht C. Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). *J Invasive Cardiol* 2005;17:199-202
 27. Dibra A; Kastrati A; Schuhlen H; Schomig A. The relationship between hospital or operator volume and outcomes of coronary patients undergoing percutaneous coronary interventions. *Z Kardiol* 2005;94:231-8
 28. von Beckerath N; von Beckerath O; Koch W; Eichinger M; Schomig A; Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. *Blood Coagul Fibrinolysis* 2005;16:199-204
 29. Mehilli J; Ndrepepa G; Kastrati A; Nekolla SG; Markwardt C; Bollwein H; Pache J; Martinoff S; Dirschinger J; Schwaiger M; Schomig A. Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. *J Am Coll Cardiol* 2005;45:828-31
 30. Schomig A; Kastrati A. Distal embolic protection in patients with acute myocardial infarction: attractive concept but no evidence of benefit. *JAMA* 2005;293:1116-8
 31. Pache J; Dibra A; Mehilli J; Dirschinger J; Schomig A; Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. *Eur Heart J* 2005;26:1262-8
 32. Schomig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schuhlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A; Intracoronary S; Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study I. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. *Eur Heart J* 2005;26:1379-84

33. Ndrepepa G; Braun S; Mehilli J; von Beckerath N; Vogt W; Schomig A; Kastrati A. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. *Am J Cardiol* 2005;95:553-7
34. Finn AV; Palacios IF; Kastrati A; Gold HK. Drug-eluting stents for diabetes mellitus: a rush to judgment? *J Am Coll Cardiol* 2005;45:479-83
35. Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stover M; Wintermantel E; Kastrati A; Schomig A. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. *Arterioscler Thromb Vasc Biol* 2005;25:748-53
36. Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schuhlen H; Schmitt C; Dirschinger J; Schomig A; Investigators I-DS. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA* 2005;293:165-71
37. Steppich B; Mattisek C; Sobczyk D; Kastrati A; Schomig A; Ott I. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. *Thromb Haemost* 2005;93:35-9

2004

1. Ndrepepa G; Mehilli J; Bollwein H; Pache J; Schomig A; Kastrati A. Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus. *Am J Med* 2004;117:830-6
2. Kandzari DE; Berger PB; Kastrati A; Steinhubl SR; Mehilli J; Dotzer F; Ten Berg JM; Neumann FJ; Bollwein H; Dirschinger J; Schomig A; Investigators I-RS. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. *J Am Coll Cardiol* 2004;44:2133-6
3. Schomig A; Ndrepepa G; Mehilli J; Dirschinger J; Nekolla SG; Schmitt C; Martinoff S; Seyfarth M; Schwaiger M; Kastrati A; investigators S-s. A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. *J Am Coll Cardiol* 2004;44:2073-9
4. Mehilli J; Kastrati A; Schuhlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schomig A; Intracoronary S; Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics Study I. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. *Circulation* 2004;110:3627-35
5. Gorchakova O; von Beckerath N; Gawaz M; Mocz A; Joost A; Schomig A; Kastrati A. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. *Eur Heart J* 2004;25:1898-902
6. Kastrati A. Drug-eluting stents for secondary prevention of restenosis. *Catheter Cardiovasc Interv* 2004;63:265-6
7. Ott I; Koch W; von Beckerath N; de Waha R; Malawaniec A; Mehilli J; Schomig A; Kastrati A. Tissue factor promoter polymorphism -603 A/G is associated with myocardial infarction. *Atherosclerosis* 2004;177:189-91
8. Hausleiter J; Kastrati A; Mehilli J; Schuhlen H; Pache J; Dotzer F; Glatthor C; Siebert S; Dirschinger J; Schomig A; Investigators I-S-. A randomized trial comparing phosphorylcholine-coated stenting

with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. *J Intern Med* 2004;256:388-97

9. Koch W; Mehilli J; Pfeufer A; Schomig A; Kastrati A. Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting. *J Lipid Res* 2004;45:2221-6
10. Pinkau T; Mann JF; Ndrepepa G; Mehilli J; Hadamitzky M; Braun S; Kastrati A; Schomig A. Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. *Am J Kidney Dis* 2004;44:627-35
11. Ndrepepa G; Mehilli J; Schwaiger M; Nekolla S; Schmitt C; Dirschinger J; Schomig A; Kastrati A. Myocardial salvage after reduced-dose thrombolysis combined with glycoprotein IIb/IIIa blockade versus thrombolysis alone in patients with acute myocardial infarction. *J Thromb Thrombolysis* 2004;17:191-7
12. Ndrepepa G; Kastrati A; Neumann FJ; Schmitt C; Mehilli J; Schomig A. Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting. *Eur Heart J* 2004;25:1635-40
13. Hausleiter J; Kastrati A; Mehilli J; Vogeser M; Zohlnhofer D; Schuhlen H; Goos C; Pache J; Dotzer F; Pogatsa-Murray G; Dirschinger J; Heemann U; Schomig A; Investigators O. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. *Circulation* 2004;110:790-5
14. Taubert D; Kastrati A; Harlfinger S; Gorchakova O; Lazar A; von Beckerath N; Schomig A; Schomig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. *Thromb Haemost* 2004;92:311-6
15. Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. *Circulation* 2004;110:1916-9
16. Pache J; Kastrati A; Mehilli J; Bollwein H; Ndrepepa G; Schuhlen H; Martinoff S; Seyfarth M; Nekolla S; Dirschinger J; Schwaiger M; Schomig A. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. *Am Heart J* 2004;148:e3
17. Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schomig A; Kastrati A; Wessely R. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. *FASEB J* 2004;18:1285-7
18. von Beckerath N; Koch W; Mehilli J; Gorchakova O; Braun S; Schomig A; Kastrati A. ABO locus O1 allele and risk of myocardial infarction. *Blood Coagul Fibrinolysis* 2004;15:61-7
19. Koch W; Jung V; von Beckerath N; Schomig A; Kastrati A. Peroxisome proliferator-activated receptor gamma gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries. *Diabetologia* 2004;47:1126-7
20. Ndrepepa G; Mehilli J; Schwaiger M; Schuhlen H; Nekolla S; Martinoff S; Schmitt C; Dirschinger J; Schomig A; Kastrati A. Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. *J Nucl Med* 2004;45:725-9
21. Kolling K; Ndrepepa G; Koch W; Braun S; Mehilli J; Schomig A; Kastrati A. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. *Am J Cardiol* 2004;93:1201-6
22. Braun S; Ndrepepa G; von Beckerath N; Vogt W; Schomig A; Kastrati A. Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. *Atherosclerosis* 2004;174:105-10

23. Kastrati A; Schomig A; Schomig E. Are we making efficient use of clopidogrel? *Eur Heart J* 2004;25:454-6
24. Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. *Am Heart J* 2004;147:457-62
25. Kastrati A; Mehilli J; Nekolla S; Bollwein H; Martinoff S; Pache J; Schuhlen H; Seyfarth M; Gawaz M; Neumann FJ; Dirschinger J; Schwaiger M; Schomig A; Investigators S-S. A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. *J Am Coll Cardiol* 2004;43:734-41
26. Sabetay C; Purcaru F; Malos A; Zavate A; Stoica A; Singer I; Ciobanu O; Jamal K; Carstoiu D; Kastrati A; Balus R. [Bowel intussusception on the child: clinical therapeutical study]. *Chirurgia (Bucur)* 2003;98:149-55
27. Hoppmann P; Koch W; Schomig A; Kastrati A. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. *Eur Heart J* 2004;25:335-41
28. Kastrati A; Mehilli J; Schlotterbeck K; Dotzer F; Dirschinger J; Schmitt C; Nekolla SG; Seyfarth M; Martinoff S; Markwardt C; Clermont G; Gerbig HW; Leiss J; Schwaiger M; Schomig A; Bavarian Reperfusion Alternatives Evaluation Study I. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2004;291:947-54
29. Schuhlen H; Kastrati A; Mehilli J; Hausleiter J; Pache J; Dirschinger J; Schomig A. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. *Am Heart J* 2004;147:317-22
30. Mehilli J; Kastrati A; Dirschinger J; Etzel L; Bollwein H; Pache J; Schuhlen H; Von Beckerath N; Seyfarth M; Schmitt C; Schomig A. Intracoronary stenting and angiographic results: Restenosis after direct stenting versus stenting with predilation in patients with symptomatic coronary artery disease (ISAR-DIRECT trial). *Catheter Cardiovasc Interv* 2004;61:190-5
31. Kastrati A; Mehilli J; Schuhlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schomig A; Intracoronary S; Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study I. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. *N Engl J Med* 2004;350:232-8
32. Gorchakova O; Koch W; Mehilli J; von Beckerath N; Schwaiger M; Schomig A; Kastrati A. PIA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction. *Thromb Haemost* 2004;91:141-5

2003

1. Koch W; Ndrepepa G; Mehilli J; Braun S; Burghartz M; Lengnick H; Kolling K; Schomig A; Kastrati A. Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries. *Arterioscler Thromb Vasc Biol* 2003;23:2229-34
2. Hausleiter J; Kastrati A; Mehilli J; Schuhlen H; Pache J; Dotzer F; Sattelberger U; Dirschinger J; Schomig A. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. *Am Heart J* 2003;146:882-6

3. Bottiger C; Koch W; Lahn C; Mehilli J; von Beckerath N; Schomig A; Kastrati A. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. *Am Heart J* 2003;146:855-61
4. Koch W; Latz W; Eichinger M; Gschwendner C; Teige B; Schomig A; Kastrati A. Haptoglobin gene subtyping by restriction enzyme analysis. *Clin Chem* 2003;49:1937-40
5. Koch W; Tiroch K; von Beckerath N; Schomig A; Kastrati A. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. *Cytokine* 2003;24:161-71
6. Neumann FJ; Kastrati A; Pogatsa-Murray G; Mehilli J; Bollwein H; Bestehorn HP; Schmitt C; Seyfarth M; Dirschinger J; Schomig A. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. *JAMA* 2003;290:1593-9
7. Roguin A; Koch W; Kastrati A; Aronson D; Schomig A; Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. *Diabetes Care* 2003;26:2628-31
8. Pesonen U; Koch W; Schomig A; Kastrati A. Leucine 7 to proline 7 polymorphism of the preproneuropeptide Y gene is not associated with restenosis after coronary stenting. *J Endovasc Ther* 2003;10:566-72
9. Schomig A; Ndrepepa G; Mehilli J; Schwaiger M; Schuhlen H; Nekolla S; Pache J; Martinoff S; Bollwein H; Kastrati A. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. *Circulation* 2003;108:1084-8
10. Mehilli J; Kastrati A; Bollwein H; Dibra A; Schuhlen H; Dirschinger J; Schomig A. Gender and restenosis after coronary artery stenting. *Eur Heart J* 2003;24:1523-30
11. Dibra A; Mehilli J; Braun S; Hadamitzky M; Baum H; Dirschinger J; Schuhlen H; Schomig A; Kastrati A. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. *Am J Med* 2003;114:715-22
12. Dibra A; Mehilli J; Schwaiger M; Schuhlen H; Bollwein H; Braun S; Neverve J; Schomig A; Kastrati A. Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. *Eur Heart J* 2003;24:1128-33
13. Koch W; Mehilli J; von Beckerath N; Bottiger C; Schomig A; Kastrati A. Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. *J Am Coll Cardiol* 2003;41:1957-61
14. Sabetay C; Singer I; Zavate A; Ciobanu O; Carstoiu E; Stoica A; Malos A; Farcas I; Kamel J; Hams I; Kastrati A. [Errors and difficulties in the diagnosis and management of acute and chronic abdomen in children]. *Chirurgia (Bucur)* 2002;97:365-71
15. Gorchakova O; Koch W; von Beckerath N; Mehilli J; Schomig A; Kastrati A. Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. *Eur Heart J* 2003;24:820-7
16. Pache J; Kastrati A; Mehilli J; Schuhlen H; Dotzer F; Hausleiter J; Fleckenstein M; Neumann FJ; Sattelberger U; Schmitt C; Muller M; Dirschinger J; Schomig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. *J Am Coll Cardiol* 2003;41:1283-8
17. Dibra A; Mehilli J; Dirschinger J; Pache J; Neverve J; Schwaiger M; Schomig A; Kastrati A. Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. *J Am Coll Cardiol* 2003;41:925-9

18. von Beckerath N; Schusterschitz Y; Koch W; Griesser K; Mehilli J; Gorchakova O; Schomig A; Kastrati A. G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease. *Atherosclerosis* 2003;167:135-9
19. Hausleiter J; Kastrati A; Mehilli J; Schuhlen H; Pache JJ; Dirschinger J; Schricke U; Schwaiger M; Markward C; Schomig A; Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction S. Impact of acute myocardial infarct location on myocardial salvage after stenting or thrombolysis (results from the STOPAMI 1 and 2 trials): Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction. *Am J Cardiol* 2003;91:341-3
20. Koch W; Ehrenhaft A; Griesser K; Pfeufer A; Muller J; Schomig A; Kastrati A. TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. *Clin Chem Lab Med* 2002;40:1123-31
21. da Costa CP; Neumann FJ; Kastrati A; Stallforth I; Schmid M; Joghetai N; Prebeck S; Wagner H; Miethke T. Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. *Atherosclerosis* 2003;166:171-6

2002

1. Hausleiter J; Kastrati A; Mehilli J; Schuhlen H; Pache J; Dotzer F; Dirschinger J; Schomig A. Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. *J Am Coll Cardiol* 2002;40:882-9
2. Schomig A; Mehilli J; Holle H; Hosl K; Kastrati D; Pache J; Seyfarth M; Neumann FJ; Dirschinger J; Kastrati A. Statin treatment following coronary artery stenting and one-year survival. *J Am Coll Cardiol* 2002;40:854-61
3. Koch W; Latz W; Eichinger M; Roguin A; Levy AP; Schomig A; Kastrati A. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. *Clin Chem* 2002;48:1377-82
4. Dong J; Ndrepepa G; Schmitt C; Mehilli J; Schmieder S; Schwaiger M; Schomig A; Kastrati A. Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. *Circulation* 2002;105:2946-9
5. Koch W; Kastrati A; Mehilli J; von Beckerath N; Schomig A. CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. *Am Heart J* 2002;143:971-6
6. Pache J; Kastrati A; Mehilli J; Gawaz M; Neumann FJ; Seyfarth M; Hall D; Braun S; Dirschinger J; Schomig A. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. *Catheter Cardiovasc Interv* 2002;55:436-41
7. Kastrati A; Mehilli J; Dirschinger J; Schricke U; Nevere J; Pache J; Martinoff S; Neumann FJ; Nekolla S; Blasini R; Seyfarth M; Schwaiger M; Schomig A; Stent versus Thrombolysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction S. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. *Lancet* 2002;359:920-5
8. Mehilli J; Kastrati A; Dirschinger J; Dotzer F; Pache J; Hausleiter J; Kramer W; Schuhlen H; Schomig A. Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. *Am J Med* 2002;112:13-8
9. Mehilli J; Kastrati A; Dirschinger J; Pache J; Seyfarth M; Blasini R; Hall D; Neumann FJ; Schomig A. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. *JAMA* 2002;287:210-5

10. Hausleiter J; Kastrati A; Mehilli J; Dotzer F; Schuhlen H; Dirschinger J; Schomig A; investigators I-ST. Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial). *Am J Cardiol* 2002;89:58-60

2001

1. Mehilli J; Kastrati A; Dirschinger J; Dotzer F; Schuhlen H; Fleckenstein M; Neumann FJ; Schomig A. A randomized trial comparing the hand-mounted JoStent with the premounted Multi-Link Duet stent in patients with coronary artery disease. *Catheter Cardiovasc Interv* 2001;54:414-9
2. Kastrati A; Hall D; Schomig A. Long-term outcome after coronary stenting. *Curr Control Trials Cardiovasc Med* 2000;1:48-54
3. Kastrati A; Schuhlen H; Schomig A. Stenting for small coronary vessels: a contestable winner. *J Am Coll Cardiol* 2001;38:1604-7
4. Koch W; Bottiger C; Mehilli J; von Beckerath N; Neumann FJ; Schomig A; Kastrati A. Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. *Am J Cardiol* 2001;88:1120-4
5. Koch W; Kastrati A; Bottiger C; Mehilli J; von Beckerath N; Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. *Atherosclerosis* 2001;159:137-44
6. Neumann FJ; Kastrati A; Miethke T; Mehilli J; Pogatsa-Murray G; Koch W; Seyfarth M; Schomig A. Previous cytomegalovirus infection and restenosis after coronary stent placement. *Circulation* 2001;104:1135-9
7. Neumann F; Kastrati A; Miethke T; Pogatsa-Murray G; Mehilli J; Valina C; Jogethaei N; da Costa CP; Wagner H; Schomig A. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. *Lancet* 2001;357:2085-9
8. Schuhlen H; Kastrati A; Pache J; Dirschinger J; Schomig A. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. *J Am Coll Cardiol* 2001;37:2066-73
9. Schuhlen H; Kastrati A; Schomig A. Images in cardiology: Structural failure of a coronary stent. *Heart* 2001;86:26
10. Kastrati A; Mehilli J; Dirschinger J; Dotzer F; Schuhlen H; Neumann FJ; Fleckenstein M; Pfafferott C; Seyfarth M; Schomig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. *Circulation* 2001;103:2816-21
11. von Beckerath N; Koch W; Mehilli J; Bottiger C; Braun S; Schomig A; Kastrati A. Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. *Atherosclerosis* 2001;156:463-8
12. Kastrati A; Dirschinger J; Schomig A. Restenosis in one lesion in patients with multilesion stenting occurs even when the companion lesion is free of restenosis. *Catheter Cardiovasc Interv* 2001;53:287-8
13. Kastrati A; Schomig A. Good medicines for bad genes. *Eur Heart J* 2001;22:523-5
14. Schuhlen H; Eigler N; Whiting JS; Haubner R; Hausleiter J; Dirschinger J; Kastrati A; Schwaiger M; Schomig A. Usefulness of intracoronary brachytherapy for in-stent restenosis with a 188Re liquid-filled balloon. *Am J Cardiol* 2001;87:463-6, A7

15. Schuhlen H; Kastrati A; Pache J; Dirschinger J; Schomig A. Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen. *Am J Cardiol* 2001;87:397-400
16. Kastrati A; Mehilli J; Dirschinger J; Pache J; Ulm K; Schuhlen H; Seyfarth M; Schmitt C; Blasini R; Neumann FJ; Schomig A. Restenosis after coronary placement of various stent types. *Am J Cardiol* 2001;87:34-9

2000

1. Kastrati A; Koch W; Berger PB; Mehilli J; Stephenson K; Neumann FJ; von Beckerath N; Bottiger C; Duff GW; Schomig A. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. *J Am Coll Cardiol* 2000;36:2168-73
2. Kastrati A; Schomig A; Dirschinger J; Mehilli J; Dotzer F; von Welser N; Neumann FJ. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. *Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation* 2000;102:2593-8
3. Mehilli J; Kastrati A; Dirschinger J; Bollwein H; Neumann FJ; Schomig A. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. *JAMA* 2000;284:1799-805
4. Schomig A; Kastrati A; Dirschinger J; Mehilli J; Schricke U; Pache J; Martinoff S; Neumann FJ; Schwaiger M. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. *N Engl J Med* 2000;343:385-91
5. Kastrati A; Koch W; Gawaz M; Mehilli J; Bottiger C; Schomig K; von Beckerath N; Schomig A. PIA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. *J Am Coll Cardiol* 2000;36:84-9
6. Koch W; Kastrati A; Mehilli J; Bottiger C; von Beckerath N; Schomig A. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. *Circulation* 2000;102:197-202
7. Kastrati A; Dirschinger J; Boekstegers P; Elezi S; Schuhlen H; Pache J; Steinbeck G; Schmitt C; Ulm K; Neumann FJ; Schomig A. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. *Catheter Cardiovasc Interv* 2000;50:290-7
8. Kastrati A; Schomig A; Dirschinger J; Mehilli J; von Welser N; Pache J; Schuhlen H; Schilling T; Schmitt C; Neumann FJ. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. *Circulation* 2000;101:2478-83
9. von Beckerath N; Koch W; Mehilli J; Bottiger C; Schomig A; Kastrati A. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. *Blood* 2000;95:3297-301
10. Bottiger C; Kastrati A; Koch W; Mehilli J; Seidl H; Schomig K; von Beckerath N; Schomig A. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. *Thromb Haemost* 2000;83:559-62
11. Neumann FJ; Kastrati A; Schmitt C; Blasini R; Hadamitzky M; Mehilli J; Gawaz M; Schlee M; Seyfarth M; Dirschinger J; Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade with

abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. *J Am Coll Cardiol* 2000;35:915-21

12. Kastrati A; Dirschinger J; Schomig A. Genetic risk factors and restenosis after percutaneous coronary interventions. *Herz* 2000;25:34-46
13. von Beckerath N; Kastrati A; Koch W; Bottiger C; Mehilli J; Seyfarth M; Schomig A. G protein beta3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. *Atherosclerosis* 2000;149:151-5
14. Kastrati A; Pache J; Dirschinger J; Neumann FJ; Walter H; Schmitt C; Schomig A. Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis. *Am Heart J* 2000;139:208-16
15. Neumann FJ; Kastrati A; Miethke T; Pogatsa-Murray G; Seyfarth M; Schomig A. Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement. *Circulation* 2000;101:11-3

1999

1. Bottiger C; Kastrati A; Koch W; Mehilli J; von Beckerath N; Dirschinger J; Gawaz M; Schomig A. Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. *Am J Cardiol* 1999;84:987-91
2. Elezi S; Kastrati A; Hadamitzky M; Dirschinger J; Neumann FJ; Schomig A. Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis. *Catheter Cardiovasc Interv* 1999;48:151-6
3. Kastrati A; Schomig A; Elezi S; Dirschinger J; Mehilli J; Schuhlen H; Blasini R; Neumann FJ. Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. *Circulation* 1999;100:1285-90
4. Schomig A; Kastrati A. Long lesions, long stents and the long process of stent optimization. *J Am Coll Cardiol* 1999;34:660-2
5. Dirschinger J; Kastrati A; Neumann FJ; Boekstegers P; Elezi S; Mehilli J; Schuhlen H; Pache J; Alt E; Blasini R; Steinbeck G; Schomig A. Influence of balloon pressure during stent placement in native coronary arteries on early and late angiographic and clinical outcome: A randomized evaluation of high-pressure inflation. *Circulation* 1999;100:918-23
6. Kastrati A; Elezi S; Dirschinger J; Hadamitzky M; Neumann FJ; Schomig A. Influence of lesion length on restenosis after coronary stent placement. *Am J Cardiol* 1999;83:1617-22
7. Wehinger A; Kastrati A; Elezi S; Baum H; Braun S; Neumann FJ; Schomig A. Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. *J Am Coll Cardiol* 1999;33:1005-12
8. Kastrati A; Schomig A; Seyfarth M; Koch W; Elezi S; Bottiger C; Mehilli J; Schomig K; von Beckerath N. PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. *Circulation* 1999;99:1005-10

1998

1. Elezi S; Kastrati A; Pache J; Wehinger A; Hadamitzky M; Dirschinger J; Neumann FJ; Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. *J Am Coll Cardiol* 1998;32:1866-73

2. Neumann FJ; Blasini R; Schmitt C; Alt E; Dirschinger J; Gawaz M; Kastrati A; Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. *Circulation* 1998;98:2695-701
3. Elezi S; Kastrati A; Neumann FJ; Hadamitzky M; Dirschinger J; Schomig A. Vessel size and long-term outcome after coronary stent placement. *Circulation* 1998;98:1875-80
4. Kastrati A; Neumann FJ; Schomig A. Operator volume and outcome of patients undergoing coronary stent placement. *J Am Coll Cardiol* 1998;32:970-6
5. Elezi S; Kastrati A; Wehinger A; Walter H; Schuhlen H; Hadamitzky M; Dirschinger J; Neumann FJ; Schomig A. Clinical and angiographic outcome after stent placement for chronic coronary occlusion. *Am J Cardiol* 1998;82:803-6, A9
6. Schuhlen H; Kastrati A; Dirschinger J; Hausleiter J; Elezi S; Wehinger A; Pache J; Hadamitzky M; Schomig A. Intracoronary stenting and risk for major adverse cardiac events during the first month. *Circulation* 1998;98:104-11
7. Kastrati A; Schomig A; Elezi S; Schuhlen H; Wilhelm M; Dirschinger J. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. *Circulation* 1998;97:2396-401
8. Ndrepepa G; Cina P; Gjini V; Kondili A; Balla I; Kastrati A. The influence of pacing rate and autonomic blockade on human primary and secondary atrial pacemakers. *Cardiologia* 1998;43:287-93

1997

1. Schomig A; Kastrati A; Elezi S; Schuhlen H; Dirschinger J; Danneegger F; Wilhelm M; Ulm K. Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. *Circulation* 1997;96:3880-7
2. Kastrati A; Schomig A; Elezi S; Schuhlen H; Dirschinger J; Hadamitzky M; Wehinger A; Hausleiter J; Walter H; Neumann FJ. Predictive factors of restenosis after coronary stent placement. *J Am Coll Cardiol* 1997;30:1428-36
3. Kastrati A; Schuhlen H; Hausleiter J; Walter H; Zitzmann-Roth E; Hadamitzky M; Elezi S; Ulm K; Dirschinger J; Neumann FJ; Schomig A. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. *Circulation* 1997;96:462-7
4. Hausleiter J; Jost S; Nolte CW; Dirschinger J; Kastrati A; Stiel GM; Wunderlich W; Fischer F; Linderer T; Hausmann D; Schomig A. Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems. *Coron Artery Dis* 1997;8:83-90
5. Schomig A; Neumann FJ; Walter H; Schuhlen H; Hadamitzky M; Zitzmann-Roth EM; Dirschinger J; Hausleiter J; Blasini R; Schmitt C; Alt E; Kastrati A. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. *J Am Coll Cardiol* 1997;29:28-34

1996

1. Schomig A; Neumann FJ; Kastrati A; Schuhlen H; Blasini R; Hadamitzky M; Walter H; Zitzmann-Roth EM; Richardt G; Alt E; Schmitt C; Ulm K. A randomized comparison of antiplatelet and

anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med* 1996;334:1084-9

1995

1. von Hoch F; Neumann FJ; Theiss W; Kastrati A; Schomig A. Efficacy and safety of collagen implants for haemostasis of the vascular access site after coronary balloon angioplasty and coronary stent implantation. A randomized study. *Eur Heart J* 1995;16:640-6

1994

1. Schomig A; Kastrati A; Mudra H; Blasini R; Schuhlen H; Klauss V; Richardt G; Neumann FJ. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. *Circulation* 1994;90:2716-24
2. Schomig A; Kastrati A; Dietz R; Rauch B; Neumann FJ; Katus HH; Busch U. Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the stented segment. *J Am Coll Cardiol* 1994;23:1053-60

1993

1. Kastrati A; Schomig A; Dietz R; Neumann FJ; Richardt G. Time course of restenosis during the first year after emergency coronary stenting. *Circulation* 1993;87:1498-505
2. Schomig A; Seyfarth M; Kastrati A. [New intervention procedures: lasers, atherectomy, stents]. *Z Kardiol* 1993;82 Suppl 5:127-31

1990

1. Kondili A; Kastrati A; Popa Y. Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. *Wien Klin Wochenschr* 1990;102:510-3

1988

1. Berisha S; Kastrati A; Goda A; Popa Y. Optimal value of filling pressure in the right side of the heart in acute right ventricular infarction. *Br Heart J* 1990;63:98-102
2. Berisha S; Goda A; Kastrati A; Frasheri A; Popa Y. Acute haemodynamic effects of nifedipine in patients with ventricular septal defect. *Br Heart J* 1988;60:149-55

Libra ose Kapituj librash

1. Zohlnhöfer D, Kastrati A. Molekulargenetische Aspekte in der Kardiologie. In: Roskamm H, Neumann FJ, Kalusche D, Bestehorn HP, eds. Herzkrankheiten. 5 ed. Berlin Heidelberg New York: Springer-Verlag; 2004:11-22.
2. Schömig A, Ndrepepa G, Kastrati A. Percutaneous coronary interventions in acute ST-segment elevation myocardial infarction. In: Topol EJ, ed. Textbook of interventional cardiology. 5 ed. Philadelphia: Saunders Elsevier; 2008:321-347.
3. Angiolillo D, Kastrati A, Simon D, eds. Clinical guide to the use of antithrombotic drugs in coronary artery disease: Informa healthcare; 2008.
4. von Beckerath N, Kastrati A. Timing, closing and length of clopidogrel therapy. In: Angiolillo D, Kastrati A, Simon D, eds. Clinical guide to the use of antithrombotic drugs in coronary artery disease: Informa healthcare; 2008:53-60.
5. Massberg M, Mehilli J, Kastrati A. The role of bivalirudin in percutaneous coronary interventions. In: Redwood S, Curzen N, Thomas MR, eds. Oxford Textbook of Interventional Cardiology. Oxford University Press; 2010:439-454.
6. Byrne RA, Joner M, Massberg S, Kastrati A. Restenosis in bare metal and drug-eluting stents. In: Escaned J, Serruys PW, eds. Coronary artery stenosis. Imaging, structure and physiology. Europa Edition; 2010:475-496.
7. Byrne RA, Kastrati A. Primary Percutaneous Coronary Intervention: Role of Stenting versus Balloon Angioplasty and Drug-Eluting Stents versus Bare Metal Stents. Trial Evidence and Current Concepts. In: Brecker S, Rothman M, eds. Clinical Guide to Primary Angioplasty. Informa healthcare; 2010:65-77.
8. Byrne RA, Kastrati A. Drug-Eluting Stent: Weighing costs and benefits. In: De Luca G, Lansky A, eds. Mechanical Reperfusion for STEMI: From Randomized Trials to Clinical Practice. Informa healthcare; 2010:114-122.
9. Schömig A, Ndrepepa G, Byrne RA, Kastrati A. Percutaneous coronary interventions in acute ST-segment elevation myocardial infarction. In: Topol EJ, Teirstein PS, ed. Textbook of interventional cardiology. 6 ed. Philadelphia: Saunders Elsevier; 2011.
10. Garg P, Kastrati A, Mauri L. Clinical Trial Design in Interventional Cardiology. In: Eeckhout E, Serruys PW, Wijns W, Vahanian A, van Sambeek M, eds. Percutaneous interventional cardiovascular medicine. The PCR-EAPCI textbook. Europa Edition; 2012.
11. Byrne RA, Joner M, Alfonso F, Kastrati A. Treatment of In-Stent Restenosis. In: Bhatt DL, ed. Cardiovascular Intervention: A Companion to Braunwald's Heart Disease: Philadelphia: Saunders Elsevier (in press).
12. Ndrepepa G, Byrne RA, Schömig A, Kastrati A. Percutaneous coronary interventions in acute ST-segment elevation myocardial infarction. In: Topol EJ, Teirstein PS, ed. Textbook of interventional cardiology. 7 ed. Philadelphia: Saunders Elsevier (in press).